

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



03 FEB 2005



(43) International Publication Date
19 February 2004 (19.02.2004)

PCT

(10) International Publication Number
WO 2004/014953 A2

(51) International Patent Classification⁷: **C07K 16/28**,
C12N 15/13, A61K 39/395, A61P 25/00, 25/16, 25/28

(74) Agents: **LEAROYD, Stephanie, Anne et al.**; Glaxo-
SmithKline, 980 Great West Road, Brentford, Middlesex
TW8 9GS (GB).

(21) International Application Number:
PCT/EP2003/008749

(22) International Filing Date: 5 August 2003 (05.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0218230.1 6 August 2002 (06.08.2002) GB
0218232.7 6 August 2002 (06.08.2002) GB
0218234.3 6 August 2002 (06.08.2002) GB
0218229.3 6 August 2002 (06.08.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **GLAXO
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ELLIS, Jonathan**,
Henry [GB/GB]; GlaxoSmithKline, Gunnels Wood
Road, Stevenage, Hertfordshire SG1 2NY (GB). **GER-
MASCHEWSKI, Volker** [DE/GB]; GlaxoSmithKline,
Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY
(GB).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: ANTIBODIES

(57) Abstract: The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formu-
lations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.

WO 2004/014953 A2

5

Antibodies**Field of the Invention**

The present invention relates to altered antibodies that bind to myelin associated glycoprotein (MAG) and neutralise the function thereof,
10 polynucleotides encoding such antibodies, pharmaceutical formulations containing said antibodies and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases. Other aspects, objects and advantages of the present invention will become apparent from the description below.

15

Background of the Invention

Stroke is a major cause of death and disability in the Western World. There is no approved therapy for the treatment of stroke other than t-PA which has to be administered within 3h of onset following a CT scan to exclude
20 haemorrhage. To date most therapeutic agents directed towards the treatment of acute stroke (i.e. neuroprotection), have predominantly involved targeting glutamate receptors and their down stream signalling pathways known to be involved in acute cell death. However to date these strategies have proved unsuccessful in clinical trials and are often associated with dose-limiting side
25 effects (Hill & Hachinski, The Lancet, 352 : (suppl III) 10-14 (1998)). Therefore there is a need for novel approaches directed towards the amelioration of cell death following the cessation of blood flow.

Following the onset of stroke, some degree of spontaneous functional recovery is observed in many patients, suggesting that the brain has the (albeit
30 limited) ability to repair and/or remodel following injury. Agents that have the potential to enhance this recovery may therefore allow intervention to be made much later (potentially days) following the onset of cerebral ischaemia. Agents which are able to offer both acute neuroprotection and enhance functional recovery may provide significant advantages over current potential
35 neuroprotective strategies.

- 5 The mechanisms underlying functional recovery are currently unknown. The sprouting of injured or non-injured axons has been proposed as one possible mechanism. However, although *in vivo* studies have shown that treatment of spinal cord injury or stroke with neurotrophic factors results in enhanced functional recovery and a degree of axonal sprouting, these do not prove a direct
- 10 link between the degree of axonal sprouting and extent of functional recovery (Jakeman, et al. 1998, Exp. Neurol. 154 : 170-184, Kawamata et al. 1997, Proc Natl Acad. Sci. USA., 94:8179-8184, Ribotta, et al. 2000, J Neurosci. 20 : 5144-5152). Furthermore, axonal sprouting requires a viable neuron. In diseases such as stroke which is associated with extensive cell death, enhancement of
- 15 functional recovery offered by a given agent post stroke may therefore be through mechanisms other than axonal sprouting such as differentiation of endogenous stem cells, activation of redundant pathways, changes in receptor distribution or excitability of neurons or glia (Fawcett & Asher, 1999, Brain Res. Bulletin, 49 : 377-391, Horner & Gage, 2000, Nature 407 963-970).
- 20 The limited ability of the central nervous system (CNS) to repair following injury is thought in part to be due to molecules within the CNS environment that have an inhibitory effect on axonal sprouting (neurite outgrowth). CNS myelin is thought to contain inhibitory molecules (Schwab ME and Caroni P (1988) J. Neurosci. 8, 2381-2193). Two myelin proteins, myelin-associated glycoprotein
- 25 (MAG) and Nogo have been cloned and identified as putative inhibitors of neurite outgrowth (Sato S. et al (1989) Biochem. Biophys. Res. Comm. 163, 1473-1480; McKerracher L et al (1994) Neuron 13, 805-811; Mukhopadhyay G et al (1994) Neuron 13, 757-767; Torigoe K and Lundborg G (1997) Exp. Neurology 150, 254-262; Schafer et al (1996) Neuron 16, 1107-1113; WO9522344;
- 30 WO9701352; Prinjha R et al (2000) Nature 403, 383-384; Chen MS et al (2000) Nature 403, 434-439; GrandPre T et al (2000) Nature 403, 439-444; US005250414A; WO200005364A1; WO0031235).

Myelin-associated glycoprotein is a cell surface transmembrane molecule expressed on the surface of myelin consisting of five extracellular

35 immunoglobulin domains, a single transmembrane domain and an intracellular

5 domain. MAG expression is restricted to myelinating glia in the CNS and peripheral nervous system (PNS). MAG is thought to interact with neuronal receptor(s) which mediate effects on the neuronal cytoskeleton including neurofilament phosphorylation and inhibition of neurite outgrowth *in vitro*. Although antagonists of MAG have been postulated as useful for the promotion
10 of axonal sprouting following injury (WO9522344, WO9701352 and WO9707810), these claims are not supported by *in vivo* data. Furthermore, the role of MAG as an inhibitor of axonal sprouting from CNS neurons *in vivo* is not proven (Li CM et al (1994) *Nature* **369**, 747-750; Montag, D et al (1994) *Neuron* **13**, 229-246; Lassmann H et al (1997) *GLIA* **19**, 104-110; Li C et al (1998) *J. Neuro. Res.* **51**, 210-217; Yin X et al (1998) *J. Neurosci.* **18**, 1953-1962; Bartsch U et al (1995) *Neuron* **15** 1375-1381; Li M et al (1996) **46**,404-414).

Antibodies typically comprise two heavy chains linked together by disulphide bonds and two light chains. Each light chain is linked to a respective heavy chain by disulphide bonds. Each heavy chain has at one end a variable
20 domain followed by a number of constant domains. Each light chain has a variable domain at one end and a constant domain at its other end. The light chain variable domain is aligned with the variable domain of the heavy chain. The light chain constant domain is aligned with the first constant domain of the heavy chain. The constant domains in the light and heavy chains are not
25 involved directly in binding the antibody to antigen.

The variable domains of each pair of light and heavy chains form the antigen binding site. The variable domains on the light and heavy chains have the same general structure and each domain comprises a framework of four regions, whose sequences are relatively conserved, connected by three
30 complementarity determining regions (CDRs) often referred to as hypervariable regions. The four framework regions largely adopt a beta-sheet conformation and the CDRs form loops connecting, and in some cases forming part of, the beta-sheet structure. The CDRs are held in close proximity by the framework regions and, with the CDRs from the other domain, contribute to the formation of
35 the antigen binding site. CDRs and framework regions of antibodies may be

- 5 determined by reference to Kabat et al ("Sequences of proteins of immunological interest" US Dept. of Health and Human Services, US Government Printing Office, 1987).

It has now been found that an anti-MAG monoclonal antibody, described (Poltorak et al (1987) *Journal of Cell Biology* **105**,1893-1899, DeBellard et al
10 (1996) *Mol. Cell. Neurosci.* **7**, 89-101; Tang et al (1997) *Mol. Cell. Neurosci.* **9**, 333-346; Torigoe K and Lundborg G (1997) *Exp. Neurology* **150**, 254-262) and commercially available (MAB1567 (Chemicon)) when administered either directly into the brain or intravenously following focal cerebral ischaemia in the rat (a model of stroke), provides neuroprotection and enhances functional recovery.
15 Therefore anti-MAG antibodies provide potential therapeutic agents for both acute neuroprotection as well as the promotion of functional recovery following stroke. This antibody is a murine antibody. Although murine antibodies are often used as diagnostic agents their utility as a therapeutic has been proven in only a few cases. Their limited application is in part due to the repeated
20 administration of murine monoclonals to humans usually elicits human immune responses against these molecules. To overcome these intrinsic undesirable properties of murine monoclonals "altered" antibodies designed to incorporate regions of human antibodies have been developed and are well established in the art. For example, a humanised antibody contains complementarity determining
25 regions ("CDR's") of non human origin and the majority of the rest of the structure is derived from a human antibody.

The process of neurodegeneration underlies many neurological diseases/disorders including acute diseases such as stroke, traumatic brain injury and spinal cord injury as well as chronic diseases including Alzheimer's disease,
30 fronto-temporal dementias (tauopathies), peripheral neuropathy, Parkinson's disease, Huntington's disease and multiple sclerosis. Anti-MAG mabs therefore may be useful in the treatment of these diseases/disorders, by both ameliorating the cell death associated with these diseases/disorders and promoting functional recovery.

35

- 5 All publications, both journal and patent, disclosed in this present specification are expressly and entirely incorporated herein by reference.

Brief Summary of the Invention

- The invention provides an altered antibody or functional fragment thereof which
 10 binds to and neutralises MAG and comprises one or more of the following CDR's. The CDR's are identified as described by Kabat (Kabat et al. (1991) Sequences of proteins of immunological interest; Fifth Edition; US Department of Health and Human Services; NIH publication No 91-3242. CDRs preferably are as defined
 15 by Kabat but following the principles of protein structure and folding as defined by Chothia and Lesk, (Chothia et al., (1989) Conformations of immunoglobulin hypervariable regions; Nature 342, p877-883) it will be appreciated that additional residues may also be considered to be part of the antigen binding region and are thus encompassed by the present invention.

20 *Light chain CDRs*

<i>CDR</i>	<i>According to Kabat</i>
L1	KSSHSVLYSSNQKNYLA (SEQUENCE ID NO: 1)
L2	WASTRES (SEQUENCE ID NO: 2)
L3	HQYLSSLT (SEQUENCE ID NO:3)

Heavy chain CDRs

<i>CDR</i>	<i>According to Kabat</i>
H1	NYGMN (SEQUENCE ID NO: 4)
H2	WINTYTGEPTYADDFTG (SEQUENCE ID NO: 5)
H3	NPINYYGINYEGYVMDY (SEQUENCE ID NO: 6)

25

5 The present invention also relates to an antibody which binds to the same epitope as an antibody having the CDRs described above. Competitive inhibition assays are used for mapping of the epitopes on an antigen. Thus there is also provided an anti-MAG antibody (altered or unaltered) which competitively inhibits the binding of the altered antibody having the CDRs described *supra* to MAG,
10 preferably human MAG.

 In a further aspect, the present invention provides an altered antibody or functional fragment thereof which comprises a heavy chain variable domain which comprises one or more CDR's selected from CDRH1, CDRH2 and CDRH3 and/or a light chain variable domain which comprises one or more CDRs selected
15 from CDRL1, CDRL2 and CDRL3.

 The invention further provides an altered anti-MAG antibody or functional fragment thereof which comprises:

- a) a heavy chain variable domain (V_H) which comprises in sequence CDRH1, CDRH2 and CDRH3,
20 and /or
- b) a light chain variable domain (V_L) which comprises in sequence CDRL1, CDRL2 and CDRL3

 A further aspect of the invention provides a pharmaceutical composition comprising an altered anti-MAG antibody of the present invention or functional
25 fragment thereof together with a pharmaceutically acceptable diluent or carrier.

 In a further aspect, the present invention provides a method of treatment or prophylaxis of stroke and other neurological diseases in a human which comprises administering to said human in need thereof an effective amount of an anti-MAG antibody of the invention or functional fragments thereof.

30 In another aspect, the invention provides the use of an anti-MAG antibody of the invention or a functional fragment thereof in the preparation of a medicament for treatment or prophylaxis of stroke and other neurological diseases.

 In a further aspect, the present invention provides a method of inhibiting
35 neurodegeneration and/or promoting functional recovery in a human patient

5 afflicted with, or at risk of developing, a stroke or other neurological disease which comprises administering to said human in need thereof an effective amount of an anti-MAG antibody of the invention or a functional fragment thereof.

10 In a yet further aspect, the invention provides the use of an anti-MAG antibody of the invention or a functional fragment thereof in the preparation of a medicament for inhibiting neurodegeneration and/or promoting functional recovery in a human patient afflicted with, or at risk of developing, a stroke and other neurological disease.

15 Other aspects and advantages of the present invention are described further in the detailed description and the preferred embodiments thereof.

Description of the Figures

Figure 1: Sequence of a mouse/human chimeric anti-MAG antibody heavy chain (Seq ID No. 27).

20 Figure 2: Sequence of a mouse/human chimeric anti-MAG antibody light chain (Seq ID No. 28).

Figure 3: Sequence of a mouse/human chimeric anti-MAG antibody heavy chain (Seq ID No. 29).

Figure 4: Chimeric anti-MAG antibody binds to rat MAG

25 Figure 5: Humanised anti-MAG antibody sequences

Figure 6: Humanised anti-MAG antibodies bind to rat MAG

Figure 7: Humanised anti-MAG antibodies bind to rat MAG

Figure 8: Humanised anti-MAG antibodies bind to human MAG

30 Figure 9: Competition ELISA with mouse and humanised anti-MAG antibodies MAG

Detailed Description of the Invention

35

5 Anti-MAG Antibody

The altered antibody of the invention is preferably a monoclonal antibody (mAb) and is preferably chimeric, humanised or reshaped, of these humanised is particularly preferred.

The altered antibody preferably has the structure of a natural antibody or
10 fragment thereof. The antibody may therefore comprise a complete antibody, a (Fab¹)₂ fragment, a Fab fragment, a light chain dimer or a heavy chain dimer. The antibody may be an IgG1, IgG2, IgG3, or IgG4; or IgM; IgA, IgE or IgD or a modified variant thereof. The constant domain of the antibody heavy chain may be selected accordingly. The light chain constant domain may be a kappa or
15 lambda constant domain. Furthermore, the antibody may comprise modifications of all classes eg IgG dimers, Fc mutants that no longer bind Fc receptors or mediate Clq binding (blocking antibodies). The antibody may also be a chimeric antibody of the type described in WO86/01533 which comprises an antigen binding region and a non-immunoglobulin region. The antigen binding
20 region is an antibody light chain variable domain or heavy chain variable domain. Typically the antigen binding region comprises both light and heavy chain variable domains. The non-immunoglobulin region is fused at its C terminus to the antigen binding region. The non-immunoglobulin region is typically a non-immunoglobulin protein and may be an enzyme, a toxin or protein having known
25 binding specificity. The two regions of this type of chimeric antibody may be connected via a cleavable linker sequence. Immunoadhesins having the CDRs as hereinbefore described are also contemplated in the present invention.

The constant region is selected according to the functionality required. Normally an IgG1 will demonstrate lytic ability through binding to complement
30 and/or will mediate ADCC (antibody dependent cell cytotoxicity). An IgG4 will be preferred if a non-cytotoxic blocking antibody is required. However, IgG4 antibodies can demonstrate instability in production and therefore it may be more preferable to modify the generally more stable IgG1. Suggested modifications are described in EPO307434 preferred modifications include at

- 5 positions 235 and 237. The invention therefore provides a lytic or a non-lytic form of an antibody according to the invention

In a preferred aspect the altered antibody is class IgG, more preferably IgG1.

10

- In preferred forms therefore the antibody of the invention is a full length non-lytic IgG1 antibody having the CDRs described *supra*. In most preferred forms we provide a full length non-lytic IgG1 antibody having the CDRs of SEQ.I.D.NO:13 and 16 and a full length non-lytic IgG1 antibody having the CDRs of SEQ.I.D.NO: 15 and 18.

- In a further aspect, the invention provides polynucleotides encoding CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3. Preferred polynucleotide sequences are
- 20 ***Light chain CDRs***

<i>CDR</i>	
L1	AAGAGCAGCCACAGCGTGCTGTACAGCAGCAA CCAGAAGAAGTACCTGGCC (SEQUENCE ID NO: 7)
L2	TGGGCCAGCACCCGCGAGAGC (SEQUENCE IDS NO: 8)
L3	CACCAGTACCTGAGCAGCCTGACC (SEQUENCE ID NO: 9)

Heavy chain CDRs

25

<i>CDR</i>	
H1	AACTACGGCATGAAC (SEQUENCE ID NO: 10)

H2	TGGATCAACACCTACACCGGCGAGCCACCTAC GCCGACGACTTCACCGGC (SEQUENCE ID NO: 11)
H3	AACCCCATCAACTACTACGGCATCAACTACGAG GGCTACGTGATGGACTAC (SEQUENCE ID NO: 12)

5

In a further aspect of the invention, there is provided a polynucleotide encoding a light chain variable region of an altered anti-MAG antibody including at least one CDR selected from CDRL1, CDRL2 and CDRL3, more preferably including all 3 CDRs in sequence.

10

In a further aspect of the invention, there is provided a polynucleotide encoding a heavy chain variable region of an altered anti-MAG antibody including at least one CDR selected from CDRH1, CDRH2 and CDRH3, more preferably including all 3 CDRs in sequence.

In a particularly preferred aspect, the anti-MAG
15 antibody of the invention is a humanised antibody.

The invention therefore further provides a humanised antibody or functional fragment thereof that binds to and neutralises MAG which comprises a heavy chain variable region comprising one of the following amino acid

20 sequences:-

QVQLVQSGSELKKPGASVKVSCKASGYTFT**NYGMN**WVRQAPGQGLEWMGWI
NTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARN**PIN**
YYGINYEGYVMDYWGQGLTVTVSS (SEQ ID No 13).

25

QVQLVQSGSELKKPGASVKVSCKASGYTFT**NYGMN**WVRQAPGQGLEWMGWI
NTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVY**FCARN**PIN
YYGINYEGYVMDYWGQGLTVTVSS (Sequence ID No 14)

30

QVQLVQSGSELKKPGASVKVSCKASGYTFT**NYGMN**WVRQAPGQGLEWMGWI
NTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTATY**FCARN**PIN
YYGINYEGYVMDYWGQGLTVTVSS (sequence ID No 15)

5 In a further aspect of the invention there is provided a humanised antibody or functional fragment thereof which binds to MAG which comprises the heavy chain variable region of Sequence ID No 13, 14 or 15 together with a light chain variable region comprising amino acid Sequences, Sequence ID No 16, 17, 18, or 19:

10

DIVMTQSPDSLAVSLGERATINCKSSHVLYSSNQKNYLAWYQQKPGQPPK
LLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYLSSLT
15 FGQGTKLEIKRTV (SEQ ID No 16)

15

DIVMTQSPDSLAVSLGERATINCKSSHVLYSSNQKNYLAWYQQKPGQPPK
LLIYWASTRESGVPDRFSGSGSGTDFTLTIIINLQAEDVAVYYCHQYLSSLT
20 FGQGTKLEIKRTV (SEQ ID No 17)

20

DIVMTQSPDSLAVSLGERATINCKSSHVLYSSNQKNYLAWYQQKPGQPPK
LLIYWASTRESGVPDRFSGSGSGTDFTLTISSLHTEDVAVYYCHQYLSSLT
25 FGQGTKLEIKRTV (SEQ ID No 18)

25

DIVMTQSPDSLAVSLGERATINCKSSHVLYSSNQKNYLAWYQQKPGQPPK
LLIYWASTRESGVPDRFSGSGSGTDFTLTIIINLHTEDVAVYYCHQYLSSLT
30 FGQGTKLEIKRTV (SEQ ID No 19)

30

In a further aspect of the present invention there is provided a humanised antibody comprising:

a heavy chain variable fragment comprising SEQ ID No13, 14 or 15

and a constant part or fragment thereof of a human heavy chain

35

and

a light chain variable fragment comprising SEQ ID No 16, 17, 18 or 19 and
a constant part or fragment thereof of a human light chain.

In a preferred aspect the humanised antibody is class 1gG more preferably 1gG1.

40

Preferred antibodies of the invention comprise:

- 5 Heavy chain variable region comprising Seq ID No 13 and light chain variable region comprising Seq ID No 16;
Heavy chain variable region comprising Seq ID No 13 and light chain variable region comprising Seq ID No 17;
Heavy chain variable region comprising Seq ID No 13 and light chain variable region comprising Seq ID No 18;
10 Heavy chain variable region comprising Seq ID No 13 and light chain variable region comprising Seq ID No 19.
Heavy chain variable region comprising Seq ID No 14 and light chain variable region comprising Seq ID No 16;
15 Heavy chain variable region comprising Seq ID No 14 and light chain variable region comprising Seq ID No 17;
Heavy chain variable region comprising Seq ID No 14 and light chain variable region comprising Seq ID No 18;
Heavy chain variable region comprising Seq ID No 14 and light chain variable region comprising Seq ID No 19.
20 Heavy chain variable region comprising Seq ID No 15 and light chain variable region comprising Seq ID No 16;
Heavy chain variable region comprising Seq ID No 15 and light chain variable region comprising Seq ID No 17;
25 Heavy chain variable region comprising Seq ID No 15 and light chain variable region comprising Seq ID No 18;
Heavy chain variable region comprising Seq ID No 15 and light chain variable region comprising Seq ID No 19.
- 30 In a further aspect, the invention provides polynucleotides encoding the heavy chain variable region comprising Sequence ID Nos 13, 14 and 15 and light chain variable regions comprising Sequence ID No 16, 17, 18 and 19.

35 Preferred polynucleotide Sequence encoding the amino acid Sequence SEQ ID NO 13 is

5 CAGGTGCAGCTGGTGCAATCTGGGTCTGAGTTGAAGAAGCCTGGGGCCTCA
GTGAAGGTTTCTGCAAGGCTTCTGGATACACCTTCACTAAACTACGGCATG
AACTGGGTGCGACAGGCCCTGGACAAGGGCTTGAGTGGATGGGATGGATC
AACACCTACACCGGCGAGCCCACCTACGCCGACGACTTCACCGGCCGTTT
GTCTTCTCCTTGGACACCTCTGT CAGCACGGCATATCTGCAGATCAGCAGC
10 CTAAAGGCTGAGGACACTGCCGTGTATTACTGTGCGAGAAACCCCATCAAC
TACTACGGCATCAACTACGAGGGCTACGTGATGGACTACTGGGGCCAGGGC
ACACTAGTCACAGTCTCCTCA (SEQ ID No 20)

15 Preferred polynucleotide sequence encoding the amino acid Sequence ID No 14
is:

CAGGTGCAGCTGGTGCAATCTGGGTCTGAGTTGAAGAAGCCTGGGGCCTCA
GTGAAGGTTTCTGCAAGGCTTCTGGATACACCTTCACTAAACTACGGCATG
AACTGGGTGCGACAGGCCCTGGACAAGGGCTTGAGTGGATGGGATGGATC
20 AACACCTACACCGGCGAGCCCACCTACGCCGACGACTTCACCGGCCGTTT
GTCTTCTCCTTGGACACCTCTGT CAGCACGGCATATCTGCAGATCAGCAGC
CTAAAGGCTGAGGACACTGCCGTGTATTTCTGTGCGAGAAACCCCATCAAC
TACTACGGCATCAACTACGAGGGCTACGTGATGGACTACTGGGGCCAGGGC
ACACTAGTCACAGTCTCCTCA (SEQ ID No 21)

25 Preferred polynucleotide sequence encoding the amino acid Sequence ID No 15
is:

CAGGTGCAGCTGGTGCAATCTGGGTCTGAGTTGAAGAAGCCTGGGGCCTCA
GTGAAGGTTTCTGCAAGGCTTCTGGATACACCTTCACTAAACTACGGCATG
30 AACTGGGTGCGACAGGCCCTGGACAAGGGCTTGAGTGGATGGGATGGATC
AACACCTACACCGGCGAGCCCACCTACGCCGACGACTTCACCGGCCGTTT
GTCTTCTCCTTGGACACCTCTGT CAGCACGGCATATCTGCAGATCAGCAGC
CTAAAGGCTGAGGACACTGCCACCTATTTCTGTGCGAGAAACCCCATCAAC
TACTACGGCATCAACTACGAGGGCTACGTGATGGACTACTGGGGCCAGGGC
35 ACACTAGTCACAGTCTCCTCA (SEQ ID No 22)

Preferred polynucleotide sequence encoding the amino acid Sequence ID No 16
is:

40 GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAG
AGGGCCACCATCAACTGCAAGAGCAGCCACAGCGTGCTGTACAGCAGCAAC
CAGAAGAAACTACCTGGCCTGGTACCAGCAGAAACCAGGACAGCCTCCTAAG
CTGCTCATTTACTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATT
45 AGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAG

5 GCTGAAGATGTGGCAGTTTATTACTGTCACCAGTACCTGAGCAGCCTGACC
TTTGGCCAGGGGACCAAGCTGGAGATCAAACGTACGGTG (SEQ ID No
23)

10 Preferred polynucleotide sequence encoding SEQ ID No 17 is:

GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAG
AGGGCCACCATCAACTGCAAGAGCAGCCACAGCGTGCTGTACAGCAGCAAC
CAGAAGAACTACCTGGCCTGGTACCAGCAGAAACCAGGACAGCCTCCTAAG
15 CTGCTCATTTACTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATT
AGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCATCAACCTGCAG
GCTGAAGATGTGGCAGTTTATTACTGTCACCAGTACCTGAGCAGCCTGACC
TTTGGCCAGGGGACCAAGCTGGAGATCAAACGTACGGTG (SEQ ID No
24)

20

Preferred polynucleotide encoding SEQ ID No 18 is:

GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAG
25 AGGGCCACCATCAACTGCAAGAGCAGCCACAGCGTGCTGTACAGCAGCAAC
CAGAAGAACTACCTGGCCTGGTACCAGCAGAAACCAGGACAGCCTCCTAAG
CTGCTCATTTACTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATT
AGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAC
ACCGAAGATGTGGCAGTTTATTACTGTCACCAGTACCTGAGCAGCCTGACC
30 TTTGGCCAGGGGACCAAGCTGGAGATCAAACGTACGGTG (SEQ ID No
25)

Preferred polynucleotide encoding SEQ ID No 19 is:

35 GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAG
AGGGCCACCATCAACTGCAAGAGCAGCCACAGCGTGCTGTACAGCAGCAAC
CAGAAGAACTACCTGGCCTGGTACCAGCAGAAACCAGGACAGCCTCCTAAG
CTGCTCATTTACTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATT
40 AGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCATCAACCTGCAC
ACCGAAGATGTGGCAGTTTATTACTGTCACCAGTACCTGAGCAGCCTGACC
TTTGGCCAGGGGACCAAGCTGGAGATCAAACGTACGGTG (SEQ ID No
26)

45 "Neutralising" refers to inhibition, either total or partial, of MAG function
including its binding to neurones and inhibition of neurite outgrowth.

5

"Altered antibody" refers to a protein encoded by an altered immunoglobulin coding region, which may be obtained by expression in a selected host cell. Such altered antibodies include engineered antibodies (e.g., chimeric, reshaped, humanized or vectored antibodies) or antibody fragments
10 lacking all or part of an immunoglobulin constant region, e.g., Fv, Fab, or F(ab)₂ and the like.

"Altered immunoglobulin coding region" refers to a nucleic acid sequence encoding altered antibody. When the altered antibody is a CDR-grafted or humanized antibody, the sequences that encode the complementarity
15 determining regions (CDRs) from a non-human immunoglobulin are inserted into a first immunoglobulin partner comprising human variable framework sequences. Optionally, the first immunoglobulin partner is operatively linked to a second immunoglobulin partner.

"First immunoglobulin partner" refers to a nucleic acid sequence encoding
20 a human framework or human immunoglobulin variable region in which the native (or naturally-occurring) CDR-encoding regions are replaced by the CDR-encoding regions of a donor antibody. The human variable region can be an immunoglobulin heavy chain, a light chain (or both chains), an analog or functional fragments thereof. Such CDR regions, located within the variable
25 region of antibodies (immunoglobulins) can be determined by known methods in the art. For example Kabat et al. (Sequences of Proteins of Immunological Interest, 4th Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987)) disclose rules for locating CDRs. In addition, computer programs are known which are useful for identifying CDR
30 regions/structures.

"Second Immunoglobulin partner" refers to another nucleotide sequence encoding a protein or peptide to which the first immunoglobulin partner is fused in frame or by means of an optional conventional linker sequence (i.e., operatively linked). Preferably it is an immunoglobulin gene. The second
35 immunoglobulin partner may include a nucleic acid sequence encoding the entire

5 constant region for the same (i.e., homologous - the first and second altered antibodies are derived from the same source) or an additional (i.e., heterologous) antibody of interest. It may be an immunoglobulin heavy chain or light chain (or both chains as part of a single polypeptide). The second immunoglobulin partner is not limited to a particular immunoglobulin class or isotype. In addition, the second immunoglobulin partner may comprise part of an immunoglobulin constant region, such as found in a Fab, or F(ab)₂ (i.e., a discrete part of an appropriate human constant region or framework region). Such second immunoglobulin partner may also comprise a sequence encoding an integral membrane protein exposed on the outer surface of a host cell, e.g., as part of a phage display library, or a sequence encoding a protein for analytical or diagnostic detection, e.g., horseradish peroxidase, β -galactosidase, etc.

The terms Fv, Fc, Fd, Fab, or F(ab)₂ are used with their standard meanings (see, e.g., Harlow et al., Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory, (1988)).

20 As used herein, an "engineered antibody" describes a type of altered antibody, i.e., a full-length synthetic antibody (e.g., a chimeric, reshaped or humanized antibody as opposed to an antibody fragment) in which a portion of the light and/or heavy chain variable domains of a selected acceptor antibody are replaced by analogous parts from one or more donor antibodies which have specificity for the selected epitope. For example, such molecules may include antibodies characterized by a humanized heavy chain associated with an unmodified light chain (or chimeric light chain), or vice versa. Engineered antibodies may also be characterized by alteration of the nucleic acid sequences encoding the acceptor antibody light and/or heavy variable domain framework regions in order to retain donor antibody binding specificity. These antibodies can comprise replacement of one or more CDRs (preferably all) from the acceptor antibody with CDRs from a donor antibody described herein.

A "chimeric antibody" refers to a type of engineered antibody which contains a naturally-occurring variable region (light chain and heavy chains)

- 5 derived from a donor antibody in association with light and heavy chain constant regions derived from an acceptor antibody.

A "humanized antibody" refers to a type of engineered antibody having its CDRs derived from a non-human donor immunoglobulin, the remaining immunoglobulin-derived parts of the molecule being derived from one (or more) human immunoglobulin(s). In addition, framework support residues may be altered to preserve binding affinity (see, e.g., Queen et al., Proc. Natl Acad Sci USA, 86:10029-10032 (1989), Hodgson et al., Bio/Technology, 9:421 (1991)). A suitable human acceptor antibody may be one selected from a conventional database, e.g., the KABAT® database, Los Alamos database, and Swiss Protein database, by homology to the nucleotide and amino acid sequences of the donor antibody. A human antibody characterized by a homology to the framework regions of the donor antibody (on an amino acid basis) may be suitable to provide a heavy chain constant region and/or a heavy chain variable framework region for insertion of the donor CDRs. A suitable acceptor antibody capable of donating light chain constant or variable framework regions may be selected in a similar manner. It should be noted that the acceptor antibody heavy and light chains are not required to originate from the same acceptor antibody. The prior art describes several ways of producing such humanised antibodies – see for example EP-A-0239400 and EP-A-054951

- 25 "Reshaped human antibody" refers to an altered antibody in which minimally at least one CDR from a first human monoclonal donor antibody is substituted for a CDR in a second human acceptor antibody. Preferably all six CDRs are replaced. More preferably an entire antigen combining region (e.g., Fv, Fab or F(ab')₂) from a first human donor monoclonal antibody is substituted for the corresponding region in a second human acceptor monoclonal antibody. Most preferably the Fab region from a first human donor is operatively linked to the appropriate constant regions of a second human acceptor antibody to form a full length monoclonal antibody.

A "vectored antibody" refers to an antibody to which an agent has been attached to improve transport through the blood brain barrier (BBB). (Review

5 see Pardridge; Advanced Drug Delivery Review 36, 299-321, 1999). The attachment may be chemical or alternatively the moiety can be engineered into the antibody. One example is to make a chimera with an antibody directed towards a brain capillary endothelial cell receptor eg an anti-insulin receptor antibody or anti-transferrin receptor antibody (Saito et al (1995) *Proc. Natl. Acad. Sci. USA* **92** 10227-31; Pardridge et al (1995) *Pharm. Res.* **12** 807-816; Broadwell et al (1996) *Exp. Neurol.* **142** 47-65; Bickel et al (1993) *Proc Natl. Acad. Sci. USA* **90**, 2618-2622; Friden et al (1996) *J. Pharm. Exp. Ther.* **278** 1491-1498, US5182107, US5154924, US5833988, US5527527). Once bound to the receptor, both components of the bispecific antibody pass across the BBB by
10 the process of transcytosis. Alternatively the agent may be a ligand which binds such cell surface receptors eg insulin, transferrin or low density lipoprotein (Descamps et al (1996) *Am. J. Physiol.* **270** H1149-H1158; Duffy et al (1987) *Brain Res.* **420** 32-38; Dehouck et al (1997) *J. Cell Biol.* **1997** 877-889). Naturally occurring peptides such as penetratin and SynB1 and Syn B3 which are
15 known to improve transport across the BBB can also be used (Rouselle et al (2000) *Mol. Pharm.* **57**, 679-686 and Rouselle et al (2001) *Journal of Pharmacology and Experimental Therapeutics* **296**, 124-131).

The term "donor antibody" refers to an antibody (monoclonal, or recombinant) which contributes the amino acid sequences of its variable regions, CDRs, or other functional fragments or analogs thereof to a first immunoglobulin
25 partner, so as to provide the altered immunoglobulin coding region and resulting expressed altered antibody with the antigenic specificity and neutralizing activity characteristic of the donor antibody.

The term "acceptor antibody" refers to an antibody (monoclonal, or recombinant) heterologous to the donor antibody, which contributes all (or any
30 portion, but preferably all) of the amino acid sequences encoding its heavy and/or light chain framework regions and/or its heavy and/or light chain constant regions to the first immunoglobulin partner. Preferably a human antibody is the acceptor antibody.

- 5 "CDRs" are defined as the complementarity determining region amino acid sequences of an antibody which are the hypervariable regions of immunoglobulin heavy and light chains. See, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 4th Ed., U.S. Department of Health and Human Services, National
10 Institutes of Health (1987). There are three heavy chain and three light chain CDRs (or CDR regions) in the variable portion of an immunoglobulin. Thus, "CDRs" as used herein refers to all three heavy chain CDRs, or all three light chain CDRs (or both all heavy and all light chain CDRs, if appropriate). The structure and protein folding of the antibody may mean that other residues are
15 considered part of the antigen binding region and would be understood to be so by a skilled person. See for example Chothia et al., (1989) Conformations of immunoglobulin hypervariable regions; Nature 342, p877-883. For convenience the CDR's as defined by Kabat in SEQ ID Nos 13-26 are underlined.
- 20 CDRs provide the majority of contact residues for the binding of the antibody to the antigen or epitope. CDRs of interest in this invention are derived from donor antibody variable heavy and light chain sequences, and include analogs of the naturally occurring CDRs, which analogs also share or retain the same antigen binding specificity and/or neutralizing ability as the donor antibody
25 from which they were derived.
- A "functional fragment" is a partial heavy or light chain variable sequence (e.g., minor deletions at the amino or carboxy terminus of the immunoglobulin variable region) which retains the same antigen binding specificity and/or neutralizing ability as the antibody from which the fragment was derived.
- 30 An "analog" is an amino acid sequence modified by at least one amino acid, wherein said modification can be chemical or a substitution or a rearrangement of a few amino acids (i.e., no more than 10), which modification permits the amino acid sequence to retain the biological characteristics, e.g., antigen specificity and high affinity, of the unmodified sequence. For example,
35 (silent) mutations can be constructed, via substitutions, when certain

5 endonuclease restriction sites are created within or surrounding CDR-encoding regions. The present invention contemplates the use of analogs of the antibody of the invention. It is well known that minor changes in amino acid or nucleic acid sequences may lead eg to an allelic form of the original protein which retains substantially similar properties. Thus analogs of the antibody of the
10 invention includes those in which the CDRs in the hypervariable region of the heavy and light chains are at least 80% homologous, preferably at least 90 % homologous and more preferably at least 95 % homologous to the CDRs as defined above as CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 and retain MAG neutralising activity. Amino acid sequences are at least 80%
15 homologous if they have 80% identical amino acid residues in a like position when the sequences are aligned optimally, gaps or insertions being counted as non-identical residues. The invention also contemplates analogs of the antibodies of the invention wherein the framework regions are at least 80%, preferably at least 90% and more preferably at least 95% homologous to the framework
20 regions set forth in Seq ID 1 - 5. Amino acid sequences are at least 80% homologous if they have 80% identical amino acid residues in a like position when the sequences are aligned optimally, gaps or insertions being counted as non-identical residues.

25 Analogues may also arise as allelic variations. An "allelic variation or modification" is an alteration in the nucleic acid sequence. Such variations or modifications may be due to degeneracy in the genetic code or may be deliberately engineered to provide desired characteristics. These variations or modifications may or may not result in alterations in any encoded amino acid
30 sequence.

 The term "effector agents" refers to non-protein carrier molecules to which the altered antibodies, and/or natural or synthetic light or heavy chains of the donor antibody or other fragments of the donor antibody may be associated by conventional means. Such non-protein carriers can include conventional
35 carriers used in the diagnostic field, e.g., polystyrene or other plastic beads,

5 polysaccharides, e.g., as used in the BIAcore [Pharmacia] system, or other non-protein substances useful in the medical field and safe for administration to humans and animals. Other effector agents may include a macrocycle, for chelating a heavy metal atom, or radioisotopes. Such effector agents may also be useful to increase the half-life of the altered antibodies, e.g., polyethylene glycol.

10 A neutralising antibody specific for MAG has been described (Poltorak et al (1987) *Journal of Cell Biology* **105**,1893-1899, DeBellard et al (1996) *Mol. Cell. Neurosci.* **7**, 89-101; Tang et al (1997) *Mol. Cell. Neurosci.* **9**, 333-346; Torigoe K and Lundborg G (1997) *Exp. Neurology* **150**, 254-262) and is commercially available (MAB1567 (Chemicon)).

Alternatively, one can construct antibodies, altered antibodies and fragments, by immunizing a non-human species (for example, bovine, ovine, monkey, chicken, rodent (e.g., murine and rat), etc.) to generate a desirable immunoglobulin upon presentation with native MAG from any species against which antibodies cross reactive with human MAG can be generated, eg human or chicken. . Conventional hybridoma techniques are employed to provide a hybridoma cell line secreting a non-human mAb to MAG. Such hybridomas are then screened for binding using MAG coated to 384- or 96-well plates, with biotinylated MAG bound to a streptavidin coated plate. or in a homogenous europium-APC linked immunoassay using biotinylated MAG.

25 A native human antibody can be produced in a human antibody mouse such as the "Xenomouse" (Abgenix) where the mouse immunoglobulin genes have been removed and genes encoding the human immunoglobulins have been inserted into the mouse chromosome. The mice are immunised as normal and develop an antibody response that is derived from the human genes. Thus the mouse produces human antibodies obviating the need to humanize the after selection of positive hybridomas. (See Green L.L., *J Immunol Methods* 1999 Dec 10;231(1-2):11-23)

30 The present invention also includes the use of Fab fragments or F(ab')₂ fragments derived from mAbs directed against MAG. These fragments are useful

5 as agents protective *in vivo*. A Fab fragment contains the entire light chain and amino terminal portion of the heavy chain; and an F(ab')₂ fragment is the fragment formed by two Fab fragments bound by disulfide bonds. Fab fragments and F(ab')₂ fragments can be obtained by conventional means, e.g., cleavage of mAb with the appropriate proteolytic enzymes, papain and/or pepsin,
10 or by recombinant methods. The Fab and F(ab')₂ fragments are useful themselves as therapeutic or prophylactic, and as donors of sequences including the variable regions and CDR sequences useful in the formation of recombinant or humanized antibodies as described herein.

The Fab and F(ab')₂ fragments can also be constructed via a
15 combinatorial phage library (see, e.g., Winter et al., Ann. Rev. Immunol., 12:433-455 (1994)) or via immunoglobulin chain shuffling (see, e.g., Marks et al., Bio/Technology, 10:779-783 (1992), which are both hereby incorporated by reference in their entirety.

Thus human antibody fragments (Fv, scFv, Fab) specific for MAG can be
20 isolated using human antibody fragment phage display libraries. A library of bacteriophage particles, which display the human antibody fragment proteins, are panned against the MAG protein. Those phage displaying antibody fragments that bind the MAG are retained from the library and clonally amplified. The human antibody genes are then excised from the specific bacteriophage and
25 inserted into human IgG expression constructs containing the human IgG constant regions to form the intact human IgG molecule with the variable regions from the isolated bacteriophage specific for MAG.

The donor antibodies may contribute sequences, such as variable heavy and/or light chain peptide sequences, framework sequences, CDR sequences,
30 functional fragments, and analogs thereof, and the nucleic acid sequences encoding them, useful in designing and obtaining various altered antibodies which are characterized by the antigen binding specificity of the donor antibody.

Taking into account the degeneracy of the genetic code, various coding sequences may be constructed which encode the variable heavy and light chain
35 amino acid sequences, and CDR sequences as well as functional fragments and

5 analogs thereof which share the antigen specificity of the donor antibody.

Isolated nucleic acid sequences, or fragments thereof, encoding the variable chain peptide sequences or CDRs can be used to produce altered antibodies, e.g., chimeric or humanized antibodies, or other engineered antibodies when operatively combined with a second immunoglobulin partner.

10 Altered immunoglobulin molecules can encode altered antibodies which include engineered antibodies such as chimeric antibodies and humanized antibodies. A desired altered immunoglobulin coding region contains CDR-encoding regions that encode peptides having the antigen specificity of an anti-MAG antibody, preferably a high affinity antibody, inserted into a first
15 immunoglobulin partner (a human framework or human immunoglobulin variable region).

Preferably, the first immunoglobulin partner is operatively linked to a second immunoglobulin partner. The second immunoglobulin partner is defined above, and may include a sequence encoding a second antibody region of
20 interest, for example an Fc region. Second immunoglobulin partners may also include sequences encoding another immunoglobulin to which the light or heavy chain constant region is fused in frame or by means of a linker sequence. Engineered antibodies directed against functional fragments or analogs of MAG may be designed to elicit enhanced binding.

25 The second immunoglobulin partner may also be associated with effector agents as defined above, including non-protein carrier molecules, to which the second immunoglobulin partner may be operatively linked by conventional means.

Fusion or linkage between the second immunoglobulin partners, e.g.,
30 antibody sequences, and the effector agent may be by any suitable means, e.g., by conventional covalent or ionic bonds, protein fusions, or hetero-bifunctional cross-linkers, e.g., carbodiimide, glutaraldehyde, and the like. Such techniques are known in the art and readily described in conventional chemistry and biochemistry texts.

5 Additionally, conventional linker sequences which simply provide for a desired amount of space between the second immunoglobulin partner and the effector agent may also be constructed into the altered immunoglobulin coding region. The design of such linkers is well known to those of skill in the art. In further aspects of the invention we provide diabodies (bivalent or bispecific),
10 triabodies, tetrabodies and other multivalent scFV protein species having one or more CDRs as described *supra* that bind to and neutralise MAG function.

 In still a further embodiment, the antibody of the invention may have attached to it an additional agent. For example, the procedure of recombinant DNA technology may be used to produce an engineered antibody of the invention
15 in which the Fc fragment or CH2-CH3 domain of a complete antibody molecule has been replaced by an enzyme or other detectable molecule (i.e., a polypeptide effector or reporter molecule).

 The second immunoglobulin partner may also be operatively linked to a non-immunoglobulin peptide, protein or fragment thereof heterologous to the
20 CDR-containing sequence having the antigen specificity of anti-MAG antibody. The resulting protein may exhibit both anti-MAG antigen specificity and characteristics of the non-immunoglobulin upon expression. That fusion partner characteristic may be, e.g., a functional characteristic such as another binding or receptor domain, or a therapeutic characteristic if the fusion partner is itself a
25 therapeutic protein, or additional antigenic characteristics.

 Another desirable protein of this invention may comprise a complete antibody molecule, having full length heavy and light chains, or any discrete fragment thereof, such as the Fab or F(ab')₂ fragments, a heavy chain dimer, or any minimal recombinant fragments thereof such as an F_v or a single-chain
30 antibody (SCA) or any other molecule with the same specificity as the selected donor mAb. Such protein may be used in the form of an altered antibody, or may be used in its unfused form.

 Whenever the second immunoglobulin partner is derived from an antibody different from the donor antibody, e.g., any isotype or class of immunoglobulin
35 framework or constant regions, an engineered antibody results. Engineered

5 antibodies can comprise immunoglobulin (Ig) constant regions and variable framework regions from one source, e.g., the acceptor antibody, and one or more (preferably all) CDRs from the donor antibody. In addition, alterations, e.g., deletions, substitutions, or additions, of the acceptor mAb light and/or heavy variable domain framework region at the nucleic acid or amino acid levels, 10 or the donor CDR regions may be made in order to retain donor antibody antigen binding specificity.

Such engineered antibodies are designed to employ one (or both) of the variable heavy and/or light chains of the anti-MAG mAb or one or more of the heavy or light chain CDRs. The engineered antibodies may be neutralising, as 15 above defined.

Such engineered antibodies may include a humanized antibody containing the framework regions of a selected human immunoglobulin or subtype, or a chimeric antibody containing the human heavy and light chain constant regions fused to the anti-MAG antibody functional fragments. A suitable human (or other 20 animal) acceptor antibody may be one selected from a conventional database, e.g., the KABAT® database, Los Alamos database, and Swiss Protein database, by homology to the nucleotide and amino acid sequences of the donor antibody. A human antibody characterized by a homology to the framework regions of the donor antibody (on an amino acid basis) may be suitable to provide a heavy 25 chain constant region and/or a heavy chain variable framework region for insertion of the donor CDRs. A suitable acceptor antibody capable of donating light chain constant or variable framework regions may be selected in a similar manner. It should be noted that the acceptor antibody heavy and light chains are not required to originate from the same acceptor antibody.

30 Desirably the heterologous framework and constant regions are selected from human immunoglobulin classes and isotypes, such as IgG (subtypes 1 through 4), IgM, IgA, and IgE. However, the acceptor antibody need not comprise only human immunoglobulin protein sequences. For instance a gene may be constructed in which a DNA sequence encoding part of a human 35 immunoglobulin chain is fused to a DNA sequence encoding a non-

- 5 immunoglobulin amino acid sequence such as a polypeptide effector or reporter molecule.

Preferably, in a humanized antibody, the variable domains in both human heavy and light chains have been engineered by one or more CDR replacements. It is possible to use all six CDRs, or various combinations of less than the six
10 CDRs. Preferably all six CDRs are replaced. It is possible to replace the CDRs only in the human heavy chain, using as light chain the unmodified light chain from the human acceptor antibody. Alternatively, a compatible light chain may be selected from another human antibody by recourse to the conventional antibody databases. The remainder of the engineered antibody may be derived
15 from any suitable acceptor human immunoglobulin.

The engineered humanized antibody thus preferably has the structure of a natural human antibody or a fragment thereof, and possesses the combination of properties required for effective therapeutic use.

It will be understood by those skilled in the art that an engineered
20 antibody may be further modified by changes in variable domain amino acids without necessarily affecting the specificity and high affinity of the donor antibody (i.e., an analog). It is anticipated that heavy and light chain amino acids may be substituted by other amino acids either in the variable domain frameworks or CDRs or both.

25 In addition, the constant region may be altered to enhance or decrease selective properties of the molecules of the instant invention. For example, dimerization, binding to Fc receptors, or the ability to bind and activate complement (see, e.g., Angal et al., *Mol. Immunol.*, 30:105-108 (1993), Xu et al., *J. Biol. Chem.*, 269:3469-3474 (1994), Winter et al., EP 307,434-B).

30 An altered antibody which is a chimeric antibody differs from the humanized antibodies described above by providing the entire non-human donor antibody heavy chain and light chain variable regions, including framework regions, in association with immunoglobulin constant regions from other species, preferably human for both chains.

5 Preferably, the variable light and/or heavy chain sequences and the CDRs of suitable donor mAbs, and their encoding nucleic acid sequences, are utilized in the construction of altered antibodies, preferably humanized antibodies, of this invention, by the following process. The same or similar techniques may also be employed to generate other embodiments of this invention.

10 A hybridoma producing a selected donor mAb is conventionally cloned, and the DNA of its heavy and light chain variable regions obtained by techniques known to one of skill in the art, e.g., the techniques described in Sambrook *et al.*, (Molecular Cloning (A Laboratory Manual), 2nd edition, Cold Spring Harbor Laboratory (1989)). The variable heavy and light regions containing at least the
15 CDR-encoding regions and those portions of the acceptor mAb light and/or heavy variable domain framework regions required in order to retain donor mAb binding specificity, as well as the remaining immunoglobulin-derived parts of the antibody chain derived from a human immunoglobulin are obtained using polynucleotide primers and reverse transcriptase. The CDR-encoding regions are
20 identified using a known database and by comparison to other antibodies.

A mouse/human chimeric antibody may then be prepared and assayed for binding ability. Such a chimeric antibody contains the entire non-human donor antibody V_H and V_L regions, in association with human Ig constant regions for both chains.

25 Homologous framework regions of a heavy chain variable region from a human antibody may be identified using computerized databases, e.g., KABAT®, and a human antibody having homology to the donor antibody will be selected as the acceptor antibody. A suitable light chain variable framework region can be designed in a similar manner.

30 A humanized antibody may be derived from the chimeric antibody, or preferably, made synthetically by inserting the donor mAb CDR-encoding regions from the heavy and light chains appropriately within the selected heavy and light chain framework. Alternatively, a humanized antibody can be made using standard mutagenesis techniques. Thus, the resulting humanized antibody
35 contains human framework regions and donor mAb CDR-encoding regions.

- 5 There may be subsequent manipulation of framework residues. The resulting humanized antibody can be expressed in recombinant host cells, e.g., COS, CHO or myeloma cells.

A conventional expression vector or recombinant plasmid is produced by placing these coding sequences for the antibody in operative association with
10 conventional regulatory control sequences capable of controlling the replication and expression in, and/or secretion from, a host cell. Regulatory sequences include promoter sequences, e.g., CMV promoter, and signal sequences, which can be derived from other known antibodies. Similarly, a second expression vector can be produced having a DNA sequence which encodes a complementary
15 antibody light or heavy chain. Preferably this second expression vector is identical to the first except insofar as the coding sequences and selectable markers are concerned, so to ensure as far as possible that each polypeptide chain is functionally expressed. Alternatively, the heavy and light chain coding sequences for the altered antibody may reside on a single vector.

- 20 A selected host cell is co-transfected by conventional techniques with both the first and second vectors (or simply transfected by a single vector) to create the transfected host cell of the invention comprising both the recombinant or synthetic light and heavy chains. The transfected cell is then cultured by conventional techniques to produce the engineered antibody of the invention.
- 25 The humanized antibody which includes the association of both the recombinant heavy chain and/or light chain is screened from culture by appropriate assay, such as ELISA or RIA. Similar conventional techniques may be employed to construct other altered antibodies and molecules.

Suitable vectors for the cloning and subcloning steps employed in the
30 methods and construction of the compositions of this invention may be selected by one of skill in the art. For example, the conventional pUC series of cloning vectors, may be used. One vector, pUC19, is commercially available from supply houses, such as Amersham (Buckinghamshire, United Kingdom) or Pharmacia (Uppsala, Sweden). Additionally, any vector which is capable of replicating
35 readily, has an abundance of cloning sites and selectable genes (e.g., antibiotic

5 resistance), and is easily manipulated may be used for cloning. Thus, the selection of the cloning vector is not a limiting factor in this invention.

Similarly, the vectors employed for expression of the antibodies may be selected by one of skill in the art from any conventional vector. The vectors also contain selected regulatory sequences (such as CMV promoters) which direct the
10 replication and expression of heterologous DNA sequences in selected host cells. These vectors contain the above described DNA sequences which code for the antibody or altered immunoglobulin coding region. In addition, the vectors may incorporate the selected immunoglobulin sequences modified by the insertion of desirable restriction sites for ready manipulation.

15 The expression vectors may also be characterized by genes suitable for amplifying expression of the heterologous DNA sequences, e.g., the mammalian dihydrofolate reductase gene (DHFR). Other preferable vector sequences include a poly A signal sequence, such as from bovine growth hormone (BGH) and the betaglobin promoter sequence (betaglopro). The expression vectors useful
20 herein may be synthesized by techniques well known to those skilled in this art.

The components of such vectors, e.g. replicons, selection genes, enhancers, promoters, signal sequences and the like, may be obtained from commercial or natural sources or synthesized by known procedures for use in directing the expression and/or secretion of the product of the recombinant DNA
25 in a selected host. Other appropriate expression vectors of which numerous types are known in the art for mammalian, bacterial, insect, yeast, and fungal expression may also be selected for this purpose.

The present invention also encompasses a cell line transfected with a recombinant plasmid containing the coding sequences of the antibodies or
30 altered immunoglobulin molecules thereof. Host cells useful for the cloning and other manipulations of these cloning vectors are also conventional. However, most desirably, cells from various strains of *E. coli* are used for replication of the cloning vectors and other steps in the construction of altered antibodies of this invention.

5 Suitable host cells or cell lines for the expression of the antibody of the invention are preferably mammalian cells such as NS0, Sp2/0, CHO, COS, a fibroblast cell (e.g., 3T3), and myeloma cells, and more preferably a CHO or a myeloma cell. Human cells may be used, thus enabling the molecule to be modified with human glycosylation patterns. Alternatively, other eukaryotic cell
10 lines may be employed. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Sambrook *et al.*, cited above.

 Bacterial cells may prove useful as host cells suitable for the expression of
15 the recombinant Fabs of the present invention (see, e.g., Plückthun, A., Immunol. Rev., 130:151-188 (1992)). However, due to the tendency of proteins expressed in bacterial cells to be in an unfolded or improperly folded form or in a non-glycosylated form, any recombinant Fab produced in a bacterial cell would have to be screened for retention of antigen binding ability. If the molecule
20 expressed by the bacterial cell was produced in a properly folded form, that bacterial cell would be a desirable host. For example, various strains of *E. coli* used for expression are well-known as host cells in the field of biotechnology. Various strains of *B. subtilis*, *Streptomyces*, other bacilli and the like may also be employed in this method.

25 Where desired, strains of yeast cells known to those skilled in the art are also available as host cells, as well as insect cells, e.g. *Drosophila* and *Lepidoptera* and viral expression systems. See, e.g. Miller *et al.*, Genetic Engineering, 8:277-298, Plenum Press (1986) and references cited therein.

 The general methods by which the vectors may be constructed, the
30 transfection methods required to produce the host cells of the invention, and culture methods necessary to produce the altered antibody of the invention from such host cell are all conventional techniques. Likewise, once produced, the antibodies of the invention may be purified from the cell culture contents according to standard procedures of the art, including ammonium sulfate
35 precipitation, affinity columns, column chromatography, gel electrophoresis and

5 the like. Such techniques are within the skill of the art and do not limit this invention. For example, preparation of altered antibodies are described in WO 99/58679 and WO 96/16990.

Yet another method of expression of the antibodies may utilize expression in a transgenic animal, such as described in U. S. Patent No. 4,873,316. This
10 relates to an expression system using the animal's casein promoter which when transgenically incorporated into a mammal permits the female to produce the desired recombinant protein in its milk.

Once expressed by the desired method, the antibody is then examined for *in vitro* activity by use of an appropriate assay. Presently conventional ELISA
15 assay formats are employed to assess qualitative and quantitative binding of the antibody to MAG. Additionally, other *in vitro* assays may also be used to verify neutralizing efficacy prior to subsequent human clinical studies performed to evaluate the persistence of the antibody in the body despite the usual clearance mechanisms.

20 The therapeutic agents of this invention may be administered as a prophylactic or post injury, or as otherwise needed. The dose and duration of treatment relates to the relative duration of the molecules of the present invention in the human circulation, and can be adjusted by one of skill in the art depending upon the condition being treated and the general health of the
25 patient.

The mode of administration of the therapeutic agent of the invention may be any suitable route which delivers the agent to the host. The antagonists and antibodies, and pharmaceutical compositions of the invention are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly,
30 intravenously, or intranasally.

Therapeutic agents of the invention may be prepared as pharmaceutical compositions containing an effective amount of the antagonist or antibody of the invention as an active ingredient in a pharmaceutically acceptable carrier. In the prophylactic agent of the invention, an aqueous suspension or solution
35 containing the engineered antibody, preferably buffered at physiological pH, in a

5 form ready for injection is preferred. The compositions for parenteral
administration will commonly comprise a solution of the antagonist or antibody of
the invention or a cocktail thereof dissolved in an pharmaceutically acceptable
carrier, preferably an aqueous carrier. A variety of aqueous carriers may be
employed, e.g., 0.9% saline, 0.3% glycine, and the like. These solutions are
10 sterile and generally free of particulate matter. These solutions may be sterilized
by conventional, well known sterilization techniques (e.g., filtration). The
compositions may contain pharmaceutically acceptable auxiliary substances as
required to approximate physiological conditions such as pH adjusting and
buffering agents, etc. The concentration of the antagonist or antibody of the
15 invention in such pharmaceutical formulation can vary widely, i.e., from less than
about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight
and will be selected primarily based on fluid volumes, viscosities, etc., according
to the particular mode of administration selected.

Thus, a pharmaceutical composition of the invention for intramuscular
20 injection could be prepared to contain 1 mL sterile buffered water, and between
about 1 ng to about 100 mg, e.g. about 50 ng to about 30 mg or more
preferably, about 5 mg to about 25 mg, of an antagonist or antibody of the
invention. Similarly, a pharmaceutical composition of the invention for
intravenous infusion could be made up to contain about 250 ml of sterile Ringer's
25 solution, and about 1 to about 30 and preferably 5 mg to about 25 mg of an
engineered antibody of the invention. Actual methods for preparing parenterally
administrable compositions are well known or will be apparent to those skilled in
the art and are described in more detail in, for example, Remington's
Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton,
30 Pennsylvania.

It is preferred that the therapeutic agent of the invention, when in a
pharmaceutical preparation, be present in unit dose forms. The appropriate
therapeutically effective dose can be determined readily by those of skill in the
art. To effectively treat stroke and other neurological diseases in a human, one
35 dose of up to 700 mg per 70 kg body weight of an antagonist or antibody of this

- 5 invention should be administered parenterally, preferably *i.v.* or *i.m.*
(intramuscularly). Such dose may, if necessary, be repeated at appropriate time
intervals selected as appropriate by a physician.

The antibodies described herein can be lyophilized for storage and
reconstituted in a suitable carrier prior to use. This technique has been shown to
10 be effective with conventional immunoglobulins and art-known lyophilization and
reconstitution techniques can be employed.

In another aspect, the invention provides a pharmaceutical composition
comprising anti-MAG antibody of the present invention or a functional fragment
thereof and a pharmaceutically acceptable carrier for treatment or prophylaxis of
15 stroke and other neurological diseases.

In a yet further aspect, the invention provides a pharmaceutical
composition comprising the anti-MAG antibody of the present invention or a
functional fragment thereof and a pharmaceutically acceptable carrier for
inhibiting neurodegeneration and/or promoting functional recovery in a human
20 patient suffering, or at risk of developing, a stroke or other neurological disease.

The following examples illustrate the invention.

Example 1 – Anti-MAG antibody in stroke model

Materials and Methods

25 *Anti-MAG monoclonal antibody*

Anti-MAG monoclonal antibody was mouse anti-chick MAG antibody MAB
1567 obtained from Chemicon. The antibody has the following characteristics:

Antigen: myelin-associated glycoprotein (human, mouse, rat, bovine,
chick, frog)

30 Isotype: IgG1

Neutralising ability: see DeBellard et al (1996) *Mol. Cell. Neurosci.* **7**, 89-
101; Tang et al (1997) *Mol. Cell. Neurosci.* **9**, 333-346; Torigoe K and Lundborg
G (1997) *Exp. Neurology* **150**, 254-262.

Control IgG1 mab was purchased from R+D Systems.

35

5 *Intra-cerebral ventricular cannulation (for study 1 only)*

Under halothane anaesthesia intra-cerebral ventricular (i.c.v.) cannulae were positioned in the left lateral cerebral ventricle (coordinates :1.6mm from the midline, 0.8mm caudal from bregma, 4.1mm from skull surface, incisor bar – 3.2mm below zero according to Paxinos and Watson, 1986) All rats were singly
10 housed to avoid damage to the guide or dummy cannula. 7 days following surgery, correct cannula placement was verified by an intense drinking response to Angiotensin II (100ng, Simpson, et al. 1978). Nine days later, animals underwent cerebral ischaemia.

15 *Transient Focal Cerebral Ischaemia*

Transient (90 min) focal cerebral ischaemia was induced in male Sprague Dawley rats, each weighing between 300-350g. The animals were initially anaesthetised with a mixture of 5% halothane, 60% nitrous oxide and 30% oxygen, placed on a facemask and anaesthesia subsequently maintained at 1.5%
20 halothane. Middle cerebral artery occlusion (MCAO) was carried out using the intraluminal thread technique as described previously (Zea Longa, et. al., 1989). Animals were maintained normothermic throughout the surgical procedure, allowed to recover for 1h in an incubator, before being singly housed. Only those animals with a neurological score of 3 1h post-occlusion were included in
25 the study (as assessed using a 5-point scoring system: 0, no deficit; 1, contralateral reflex; 2, weakened grip; 3, circling; 4, immobile; 5, dead). Animals were maintained for up to 1 week at which time animals were killed by transcardial perfusion of 0.9% saline followed by 4% paraformaldehyde in 100mM phosphate buffer. The brains were post-fixed in 4% paraformaldehyde
30 at 4°C for 48h at which time they were removed from the skulls and cut into 2mm blocks using a rat brain matrix. The 2mm sections were then paraffin embedded using a Shandon Citadel 1000 tissue processor, cut into 6µm sections using a microtome and mounted on poly-L-lysine coated slides. Sections were then processed for Cresyl Fast Violet (CFV) staining.

35

5 *Dosing regime*

Anti-MAG monoclonal antibody and mouse IgG1 isotype control antibody were dialysed against sterile 0.9 % sodium chloride overnight and concentrated appropriately.

Study 1 : Animals received 2.5µg of anti-MAGmab or 2.5µg mouse IgG i.v. 1,
10 24 and 72h following MCAO (5ul per dose).

Study 2 : Animals received 200µg of anti-MAG mab or 200µg mouse IgG i.v. 1
and 24 following MCAO.

Investigator was blinded to the identity of each dosing solution.

15 *Neurological assessment*

Prior to induction of cerebral ischaemia, rats for Study 1 received training in beam walking and sticky label test. Animals not reaching criteria in both tests were excluded from further study. Following training, the remainder of the animals were stratified according to performance into two balanced groups.

20 Throughout the neurological assessment, the investigators were blinded to the treatment group of the animal.

Bilateral Sticky label test

The bilateral sticky label test (Schallert et al., Pharmacology Biochemistry and Behaviour 16 : 455-462, (1983)) was used to assess contralateral
25 neglect/ipsilateral bias. This models tactile extinction observed in human stroke patients (Rose, et al. 1994). This test has been described in detail previously (Hunter, et al., Neuropharmacology 39 : 806-816 (2000); Virley et al Journal of Cerebral Blood Flow & Metabolism, 20 : 563-582 (2000)). Briefly, a round, sticky
30 paper label was placed firmly around the hairless area of the forepaws with equal pressure with order of placement randomised (left, right). Training sessions were conducted for 6 days prior to MCAO, day 6 data was utilised as the pre-operative baseline (Day 0). Animals were given two trials 24 and 7d following MCAO, the data represents a mean of the two trials. The latency to

- 5 contact and remove the labels were recorded and analysed using the logrank test (Cox, J. Royal Statistical Society B 34 : 187-220 (1972)).

Beam walking

- Beam walking was used as a measure of hind-limb and fore-limb co-ordination by means of distance travelled across an elevated 100cm beam (2.3cm diameter, 48 cm off the floor) as previously described in detail (Virley et al Journal of Cerebral Blood Flow & Metabolism, 20 : 563-582 (2000)). Rats were trained to cross the beam from start to finish. For testing, each rat was given 2 trials 24 h and 7d following MCAO, the data represents a mean of the two trials. Statistical analysis was ANOVA followed by Student's t-test.

The 27-point neurological score (Study-1)

- This study consists of a battery of tests to assess neurological status including, paw placement, visual forepaw reaching, horizontal bar, contralateral rotation, inclined plane, righting reflex, contralateral reflex, motility & general condition, as described previously (Hunter, et al. Neuropharmacology 39 : 806-816 (2000)) with the addition of grip strength measurements (scores 2 for good right fore-limb grip, 1 for weak grip). Total score = 27 for normal animal.

- For study 2 this test was modified further : Grip strength - normal scores 3, good - 2, weak - 1, very weak - 0; Motility - normal scores 4, excellent - 3, very good - 2, good - 1, fair - 0; General Condition - normal scores 4, excellent - 3, very good - 2, good - 1, fair - 0; Circling - none scores 5, favours one-side scores 4, large circle - 3, medium circle - 2, small circle - 1, spinning - 0). Total score = 32 for a normal animal.

- 30 In both studies animals were tested 1, 24, 48h and 7d following MCAO, a healthy normal animal scores 27 or 32 respectively. Data are presented as median values, Statistical analysis was Kruskal Wallis ANOVA.

Lesion assessment

- 5 Study 1 - For each animal, lesion areas were assessed in sections from three pre-determined levels in the brain (0, -2.0 and -6.0 mm from Bregma respectively). Neuronal damage was assessed using cresyl fast violet staining and the area of damage measured using an Optimas 6.1 imaging package. Data is expressed as mean area (mm^2) \pm sem.
- 10 Study 2 - For each animal, lesion areas were assessed in sections from seven pre-determined levels in the brain (+3mm to -8mm w.r.t. Bregma). Neuronal damage was assessed using cresyl fast violet staining and the area of damage measured using an Optimas 6.1 imaging package. Data is expressed as mean area (mm^2) \pm sem.

15

Results

Study 1 – Intra-cerebral ventricular (i.c.v.) administration of anti-MAG mab

20 *Neurological score*

- One hour following MCAO animals in both treatment groups showed marked impairment in neurological score (median score 12 in each group). There was no significant difference between groups at this time. However, 24 ($p=0.02$), 48 ($p=0.005$) h and 7d ($p=0.006$) following MCAO animals treated
- 25 with anti-MAG mab (2.5 μg , 1, 24 and 72h post-MCAO) showed significantly improved Total Neurological score compared to those treated with control IgG. Median neurological scores 24, 48h and 7d following MCAO in the IgG₁ treated group were 15, 14 and 18 respectively compared to 19.5, 21.5 and 22 in the anti-MAG mab treated animals. On further analysis of the individual behaviours
- 30 comprising the total score, this significant improvement was mainly attributed to improved performance in the following tests : paw placement (24h, $p=0.045$; 48h, $p=0.016$; 7d, $p=0.008$), grip strength (24h, $p=0.049$ 48h, $p=0.0495$; 7d, $p=0.243$), motility (24h, $p=0.199$; 48h, $p=0.012$; 7d, $p=0.067$), horizontal bar (24h, $p=0.065$; 48h, $p=0.005$; 7d, $p=0.016$), inclined plane (24h, $p=0.006$; 48h,

- 5 $p=0.006$; 7d, $p=0.169$), visual forepaw reaching (48h, $p=0.049$, 7d, $p=0.049$) and the degree of circling (24h, $p=0.417$; 48h, $p=0.034$; 7d, $p=0.183$).

Beam Walking

Prior to surgery all animals were trained to cross the beam (100cm).

- 10 Twenty four hours following surgery there was a significant impairment on the distance travelled on the beam in both anti-MAG ($50\pm 18\text{cm}$) and IgG₁ ($22\pm 14\text{cm}$) treated animals compared to pre-operative values. Although not significant, anti-MAG treated animals showed marked improvement over IgG₁ treated animals in that they travelled twice the distance of IgG₁ treated animals
- 15 24h following tMCAO. Seven days following surgery however, while both groups showed marked improvement over time, the performance of animals treated with IgG remained significantly impaired compared to baseline ($55\pm 15\text{cm}$; $p=0.005$). In contrast however 7d following MCAO, animals treated with anti-MAG mab ($2.5\text{ }\mu\text{g}$, 1, 24 and 72h, i.c.v post MCAO) performance was not significantly different
- 20 from baseline ($75\pm 15\text{cm}$; $p=0.07$). This data shows that anti-MAG mab treatment accelerated recovery of this beam walking task compared to mouse IgG₁ treated controls.

Sticky label

- 25 Prior to surgery, animals in each of the treatment groups rapidly contacted and removed the labels from each forepaw, there was no significant difference in the groups prior to treatment (Table 1). Twenty-four hours and 7d following MCAO the latency to contact the left paw in each of the treatment groups remained relatively unaltered, while that of the right was markedly increased.
- 30 However there was no significant differences between removal times in anti-MAG and IgG₁ treated animals. In addition 24h following MCAO, the latency to removal from both the left and right forepaw was significantly increased in both treatment groups compared to baseline, however in anti-MAG treated animals the latency to removal from the left paw was significantly shorter than that of
- 35 IgG₁ treated animals ($p=0.03$). There was also a trend for reduced latency to

- 5 removal from the right paw in anti-MAG treated animals compared to those treated with IgG₁ (p=0.08) (Table 1). At 7d there was some degree of recovery in IgG₁ treated animals in that the latency to removal times for each forepaw were reduced compared to those at 24h (Table 1). This data suggests that treatment of rats with anti-MAG mab accelerate the recovery in this sticky label
- 10 test following tMCAO.

Table 1 – Sticky label data

Day	Treatment	Contact Time (s) (Mean±sem)		Removal Time (s) (Mean±sem)	
		Left Forepaw	Right Forepaw	Left Forepaw	Right Forepaw
0	Anti-MAG	2.4 ± 0.2	3.6 ± 0.5	12 ± 2	12 ± 2
0	IgG ₁	3.3 ± 0.6	4.2 ± 0.7	10 ± 1	9 ± 1
1	Anti-MAG	5.9 ± 3.7	109.6 ± 27.5	*61 ± 26	96 ± 26
1	IgG ₁	3.6 ± 0.5	71.8 ± 31.7	130 ± 21	156 ± 19
7	Anti-MAG	3.8 ± 1	36.4 ± 10.2	54 ± 23	80 ± 30
7	IgG ₁	2.8 ± 0.3	64 ± 28	23 ± 8	87 ± 20

(*p=0.03 Anti-MAG v's IgG₁ using the logrank test)

15 Lesion area measurements

Administration of anti-MAG mab i.c.v, significantly reduced lesion area in two of the three brain levels examined compared to those animals treated with equal amounts of mouse IgG₁ when examined 7 days following tMCAO (Table 2).

20

Table 2

Treatment	Mean Lesion Area ± sem (mm ²) 7d following tMCAO		
	0 mm wrt	-2 mm wrt Bregma	-6 mm wrt

	Bregma		Bregma
Anti-MAG mab (n=8)	*9 ± 2	\$4 ± 3	#3 ± 1
Mouse IgG ₁ (n=9)	14 ± 1	12 ± 1	5 ± 1

- 5 (*p=0.02, \$p=0.03, #p=0.06, anti-MAG v's IgG₁, One-way, unpaired Students T-Test)

Study 2 – Intra-venous (i.v.) administration

Neurological score

- 10 One and 24 hours following MCAO animals in both groups showed marked impairment in neurological score. There was no significant difference between groups at this time, median scores 24h following anti-MAG mab and IgG₁ treatment were 20 and 18 respectively (p=0.5). Forty-eight hours following MCAO, animals treated with anti-MAG mab (200ug, i.v. 1 and 24h post-MCAO)
- 15 showed significant improvement in paw placement (p=0.048) and grip strength (p=0.033). Seven days following the onset of cerebral ischaemia animals treated with anti-MAG mab continued to improve (paw placement p=0.041; grip strength, p=0.048; motility, p=0.05) and showed significant improvement in total neurological score (median score 25) compared to those treated with mouse IgG₁
- 20 (Median score 23, p=0.047).

Lesion area measurements

- The anti-MAG antibody when administered i.v. MCAO significantly reduced lesion area at 5 out of 7 pre-determined brain levels (+3 to -8 mm w.r.t.
- 25 Bregma) compared to isotype controls, when examined 7d following MCAO.

Brain level wrt Bregma	Mean lesion area ± SEM (mm ²) – Anti- MAG treated	Mean lesion area ± SEM (mm ²) – Mouse IgG ₁ treated
3 mm	*0.38 ± 0.27	1.77 ± 0.45
1 mm	*5.82 ± 1.65	9.627 ± 1.14
-1 mm	8.98 ± 2.58	12.07 ± 1.57

-2 mm	7.28 ± 1.92	10.04 ± 1.87
-4 mm	*5.57 ± 1.06	10.38 ± 1.39
-6 mm	*1.36 ± 0.51	4.43 ± 1.95
-8 mm	*0.27 ± 0.27	1.93 ± 0.56

5 * p < 0.05 – Unpaired, one-way Students T-test

Conclusions

An anti-MAG monoclonal antibody administered either directly into the CSF or intravenously following transient middle-cerebral artery occlusion in the rat, both reduced the area of cell death and improved functional recovery compared to control treated animals. The degree of neuroprotection seen in these studies suggests that this effect can not be attributed to axonal sprouting as this would not result in neuronal sparing. The improvement in functional recovery seen 24 and 48h following MCAO probably reflects the degree of neuroprotection offered by this antibody compared to control treated animals. However, over time the animals appear to improve further, suggesting that blocking MAG activity can also enhance functional recovery over time.

The studies presented here provide evidence that blocking the actions of MAG provide both neuroprotection and enhanced functional recovery in a rat model of stroke, and therefore anti-MAG antibodies provide potential therapeutic agents for acute neuroprotection and/or the promotion of functional recovery following stroke. The low amounts of antibody administered via the i.v route and the resulting low serum levels of the antibody would in turn suggest extremely low antibody concentrations in the brain due to the constraints of the blood brain barrier for antibody penetration. Surprisingly, however, this still resulted in both, neuroprotection and enhanced functional recovery being observed. Anti-MAG antibodies also have potential use in the treatment of other neurological disorders where the degeneration of cells and or nerve fibres is apparent such as spinal cord injury, traumatic brain injury, peripheral neuropathy, Alzheimer's disease, fronto-temporal dementias (tauopathies), Parkinson's disease, Huntington's disease and Multiple Sclerosis. In the examples that follow the CDRs of the chimeric and humanised antibodies disclosed therein are the CDRs of the antibody of example 1.

5

Example 2— Chimeric antibody

Altered antibodies include chimeric antibodies which comprise variable regions deriving from one species linked to constant regions from another species. Examples of mouse-human chimeric anti-MAG immunoglobulin chains of the invention are provided in Figures 1, 2, and 3. Mouse-human chimeras using human IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM, IgD constant regions may be produced, as may chimeras associating the mouse variable regions with heavy or light chain constant regions from non-human species.

Figure 1 (Seq ID No. 27) provides the amino acid sequence of a chimeric immunoglobulin heavy chain in which the murine anti-MAG heavy chain variable region is associated with a functional immunoglobulin secretion signal sequence, and with an altered form of the human IgG1 constant region, in which Kabat residues 248 and 250 have been mutated to alanine in order to disable the effector functions of binding to Fc γ RI and complement protein C1q (Duncan, A.R. and Winter, G. Localization of the C1q binding site on antibodies by surface scanning. Nature 332, 738-740, 1988. Duncan, A.R., Woolf, J.M., Partridge, L.J., Burton, D.R. and Winter, G. Localisation of the binding site for human FcR1 on IgG. Nature 332, 563-564, 1988). Such mutations are optionally made in order to customise the properties of an altered antibody to achieve a particular therapeutic effect – for example binding to and blocking the function of an antigen without activating lytic effector mechanisms.

Figure 2 (Seq ID No. 28) provides the amino acid sequence of a chimeric immunoglobulin light chain in which the murine anti-MAG light chain variable region is associated with a functional immunoglobulin secretion signal sequence, and with the human kappa constant region.

Similarly, the anti-MAG variable regions may be associated with immunoglobulin constant regions which lack mutations disabling effector functions. Figure 3 (Seq ID No. 29) provides the amino acid sequence of a chimeric immunoglobulin heavy chain in which the murine anti-MAG heavy chain

- 5 variable region is associated with a functional immunoglobulin secretion signal sequence, and with a wild-type form of the human IgG1 constant region.

From the information provided in Figures 1 to 3, cDNA inserts encoding these chimeric chains may be prepared by standard molecular biology techniques well known to those skilled in the art. Briefly, the genetic code is used to identify
10 nucleotide codons encoding the desired amino acids, creating a virtual cDNA sequence encoding the chimeric protein. If the cDNA insert is desired to be expressed in a particular organism, then particularly favoured codons may be selected according to known codon usage biases. The desired nucleotide sequence is then synthesised by means of PCR amplification of a template
15 comprising overlapping synthetic oligonucleotides which, as a contig, represent the desired sequence. The resulting product may also be modified by PCR or mutagenesis to attach restriction sites to facilitate cloning into a suitable plasmid for expression or further manipulations.

20 **Example 3-Chimeric antibody binds to rat MAG in ELISA**

Chimeric anti-MAG antibody containing the light and heavy chain CDRs of the invention was produced by transient transfection of CHO cells. For this, Transfast transfection reagent (Promega; E2431) was used and transfections
25 carried out according to manufacturer's instructions. In brief, $\sim 10^6$ CHO cells were plated out per well of 6-well culture plates. The following day mammalian expression vector DNA encoding the appropriate heavy or light chain were mixed at 1:1 ratio (5 μ g total DNA) in medium (Optimem1 with Glutamax; Gibco #51985-026). Transfast transfection reagent was added and the solution
30 transferred to wells with confluent cell layers. After 1h at 37°C in the cell incubator, the DNA/Transfast mixture was overlaid with 2ml Optimem medium and left for 48-72h in the incubator. Supernatants were harvested, cleared by centrifugation and passed through 0.2 μ m filters. Antibody concentration in CHO cell culture supernatant was determined by ELISA and estimated to be around
35 0.5 μ g/ml. For MAG binding, commercially available ratMAG-Fc was used. Due to the fusion with human Fc bound chimeric antibodies could not be detected

5 using anti-human IgG secondary antibodies. Instead, anti-human kappa light chain-specific antibody was used. Figure 4 shows that this chimeric antibody binds to MAG even at 1/64 dilution. An unrelated humanised antibody and culture supernatant from mock transfected cells did not generate any signal in this assay.

10

Procedure:

ELISA microtiter plates (Nunc Maxisorp) were coated with 1 µg/ml rat MAG-Fc fusion protein (R&D systems; 538-MG) in PBS at 4°C overnight. Plates were washed twice with PBS and then blocked with PBS/BSA (1% w/v) for 1h at room temperature (RT). Culture supernatants from transiently transfected CHO cells were passed through 0.2µm filters and serially diluted in PBS/BSA starting at neat supernatant to 1/64 dilution. Sample dilutions were left at RT for 1h. Plates were then washed three times with PBS/Tween 20 (0.1% v/v). Detection antibody was goat anti-human kappa light chain specific-peroxidase conjugate (Sigma A-7164) diluted at 1/2000 in PBS/BSA. The detection antibody was incubated for 1h at RT and the plates washed as above. Substrate solution (Sigma Fast OPD P-9187) was added and incubated until appropriate colour development was detected and then stopped using 3M H₂SO₄. Colour development was read at 490nm.

25 **Example 4 – Humanised antibodies**

Altered antibodies include humanised antibodies which comprise humanised variable regions linked to human constant regions. Examples of humanised anti-MAG immunoglobulin chains of the invention are provided in Figure 5. Humanised antibodies using human IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM, IgD constant regions may be produced.

Figure 5 (Seq ID No: 30) provides an example of the amino acid sequence of a humanised immunoglobulin heavy chain in which the humanised anti-MAG heavy chain variable region is associated with a functional immunoglobulin secretion signal sequence, and with an altered form of the

35

- 5 human IgG1 constant region, in which Kabat residues 248 and 250 have been mutated to alanine in order to disable the effector functions of binding to Fc γ RI and complement protein C1q (Duncan, A.R. and Winter, G. Localization of the C1q binding site on antibodies by surface scanning. *Nature* 332, 738-740, 1988. Duncan, A.R., Woolf, J.M., Partridge, L.J., Burton, D.R. and Winter, G.
- 10 Localisation of the binding site for human FcR1 on IgG. *Nature* 332, 563-564, 1988). Such mutations are optionally made in order to customise the properties of an altered antibody to achieve a particular therapeutic effect – for example binding to and blocking the function of an antigen without activating lytic effector mechanisms.
- 15 Figure 5 (Seq ID No. 31) also provides an example of the amino acid sequence of a humanised immunoglobulin light chain in which the humanised anti-MAG light chain variable region is associated with a functional immunoglobulin secretion signal sequence, and with the human kappa constant region.
- 20 Similarly, the anti-MAG variable regions may be associated with immunoglobulin constant regions which lack mutations disabling effector functions. Figure 5 (Seq ID No. 32) provides the amino acid sequence of a humanised immunoglobulin heavy chain in which the humanised anti-MAG heavy chain variable region is associated with a functional immunoglobulin secretion
- 25 signal sequence, and with a wild-type form of the human IgG1 constant region.
- From the information provided in Figure 5, cDNA inserts encoding these humanised chains may be prepared by standard molecular biology techniques well known to those skilled in the art. Briefly, the genetic code is used to identify nucleotide codons encoding the desired amino acids, creating a virtual cDNA
- 30 sequence encoding the protein. If the cDNA insert is desired to be expressed in a particular organism, then particularly favoured codons may be selected according to known codon usage biases. The desired nucleotide sequence is then synthesised by means of PCR amplification of a template comprising overlapping synthetic oligonucleotides which, as a contig, represent the desired sequence.
- 35 The resulting product may also be modified by PCR or mutagenesis to attach

- 5 restriction sites to facilitate cloning into a suitable plasmid for expression or further manipulations.

Example 5 : Humanised anti-MAG antibodies bind to rat and human

10 **MAG in Elisa**

1) Direct binding ELISA to rat MAG-Fc fusion protein of normalised amounts of culture supernatant for 9 humanised heavy and light chain combinations

15

- Humanised anti-MAG antibodies containing the light and heavy chain CDRs of the Invention were produced by transient transfection of CHO cells. For this, Transfast transfection reagent (Promega; E2431) was used and transfections carried out according to manufactures instructions. In brief, $\sim 10^6$ CHO cells
- 20 were plated out per well of 6-well culture plates. The following day mammalian expression vector DNA encoding the appropriate heavy or light chain were mixed at 1:1 ratio (5 μ g total DNA) in medium (Optimem1 with Glutamax; Gibco #51985-026). Transfast transfection reagent was added and the solution transferred to wells with confluent cell layers. After 1h at 37°C in the cell
- 25 incubator, the DNA/Transfast mixture was overlaid with 2ml Optimem medium and left for 48-72h in the incubator. Supernatants were harvested, cleared by centrifugation and passed through 0.2 μ m filters. 9 heavy and light variable chain combinations were produced from the sequences shown in the table below and the IgG1 heavy chain constant regions were functional according to Seq.ID .

30

Seq ID No (V-regions)	Description	Alternative name
13	Humanised Vh	BVh1
14	Humanised Vh	BVh2
15	Humanised Vh	BVh3
16	Humanised Vl	CVl1

17	Humanised VI	CVI2
18	Humanised VI	CVI3
19	Humanised VI	CVI4

5

Antibody concentration was determined by ELISA and the amounts of supernatant used in the assay normalised to a starting concentration of 250 or 500 ng/ml (depending on concentration of culture supernatant). As antigen, commercially available ratMAG-Fc was used (R&D Systems; 538-MG). Due to the fusion of this antigen with human Fc, bound chimeric antibodies could not be detected using general anti-human IgG secondary antibodies. Instead, anti-human kappa light chain-specific antibody was used. Figure 6 shows that all 9 humanised antibodies examined here bound to rat MAG with very similar binding curves down to ~ 4ng/ml. The chimeric antibody used as a reference showed binding characteristics that fell within the group of humanised antibodies examined here. Although not absolute, this may suggest that the affinities of the humanised antibodies examined here lie very closely within the affinity range of the non-humanised chimeric antibody used as a reference here.

20

Procedure

96-well Nunc Maxisorp plates were coated overnight at 4°C with rat MAG-Fc fusion protein (1 µg/ml; R&D Systems; Cat.No. 538-MG) in PBS. Plates were washed twice with PBS containing Tween20 (0.1% v/v; PBST) and blocked with PBS containing BSA (1%w/v) for 1h at room temperature (RT). Variable amounts of culture supernatants were serial diluted in blocking buffer and added to the blocked wells starting at approximately 500 or 250 ng/ml. Antibody concentrations of supernatants were based on independent assays measuring the amount of humanised antibody present in each culture supernatant. Chimeric mouse-human (non-humanised) antibody was also included as reference. Antibody samples were incubated 1h at RT and plates then washed 3x with PBST. Secondary antibody (Goat anti-human light chain specific-peroxidase

30

5 conjugate; Sigma A-7164) was added diluted 1/5000 in blocking buffer and incubated for 1h at RT. Wells were washed three times as above and binding detected by adding substrate (OPD tablets dissolved according to instructions; Sigma P-9187). Colour development was monitored and the reaction stopped using 3M H₂SO₄. Colour development was read at 490nm.

10

2) Direct binding ELISA to rat MAG-Fc fusion protein of two purified humanised anti-MAG antibody heavy-light chain combinations

15

Two humanised antibodies consisting of heavy and light chain variable region combinations BVh1/CVI1 and BVh3/CVI3 (table figure 5) and a mutated IgG1 constant region as exemplified by SEQ.I.D.NO:30 (which is BVh1/CVI1 mutated IgG1, those skilled in the art can readily derive the sequence for the BVh3/CVI3 equivalent) were produced by a scaled-up version of the transient transfection described in example 3 and purified using protein A affinity chromatography. Purified antibody material was dialysed against PBS and the concentration determined by OD280 reading. Antibody concentrations were adjusted to 5000 ng/ml and used as serial dilutions in a rat MAG-Fc binding ELISA. Figure 7 shows

20 that purified antibody material binds rat MAG-Fc and that both heavy and light chain variable region combinations tested here are extremely similar.

25

Method:

96-well Nunc Maxisorp plates were coated overnight at 4°C with rat MAG-Fc fusion protein (2.5 µg/ml; R&D Systems; Cat.No. 538-MG) in PBS. Plates were washed twice with PBS containing Tween20 (0.1% v/v; PBST) and blocked with PBS containing BSA (1%w/v) for 1h at room temperature (RT). Purified humanised antibody was adjusted to a starting concentration of 5 µg/ml in blocking buffer and then serial diluted. Antibody samples were incubated 1h at

30 RT and plates then washed 3x with PBST. Secondary antibody (Goat anti-human

35

5 light chain specific-peroxidase conjugate; Sigma A-7164) was added diluted
1/5000 in blocking buffer and incubated for 1h at RT. Wells were washed three
times as above and binding detected by adding substrate (OPD tablets dissolved
according to instructions; Sigma P-9187). Colour development was monitored
and the reaction stopped using 3M H₂SO₄. Colour development was read at
10 490nm.

Results:

Both purified humanised antibodies carrying none or several framework
mutations show extremely similar binding to rat MAG. The results are seen in
15 Figure 7.

3) Binding to human MAG expressed on CHO cells of normalised amounts of culture supernatant for two humanised heavy and light chain combinations

20 The same humanised variable heavy and light chain combinations described in
example 5 2) were tested as cleared culture supernatants against human MAG
expressed on the surface of CHO cells. The amount of culture supernatant used
for each antibody was normalised based on antibody concentrations determined
25 by ELISA. For this, 96-well plates (Nunc Maxisorp) were coated overnight at 4°C
with goat anti-human IgG (gamma) chain (Sigma I-3382; in bicarbonate buffer
pH9.6; 2µg/ml). Following day, plates were washed twice with wash buffer
(PBST) and blocked by adding at least 75µl blocking buffer (PBS containing BSA
1% w/v) for 1h at RT. Antibody sample solution were serial diluted in blocking
30 buffer (starting dilution neat or 1/2) in duplicate. Ab standard was purified
humanised IgG1 antibody of an unrelated specificity and known concentration.

- 5 The standard solution was also serial diluted across plate starting at 500ng/ml.
- All antibody solutions were incubated for 1h at RT. Plates were washed 3x as above and then incubated with goat anti-human light (kappa) chain specific (free and bound) peroxidase conjugate (Sigma; A-7164) at 1/5000 in blocking buffer for 1h @ RT. Plates were again washed 3x as above and incubated with
- 10 substrate solution (OPD tablets; Sigma P-9187 until strong colour development. Colour development was stopped by adding 25µl 3M H₂SO₄ and the plate read at 490nm.
- Figure 8 shows that both antibodies tested here are recognising human MAG and are very similar in their binding characteristics. CHO/- are negative controls of
- 15 CHO cells with no MAG expressed.

Method for Eu cell-based ELISA

96-well plates (Costar 3595) were filled with 100µl cell suspension/well (see table below for recommended cell number for performing assay on days 1, 2, 3 or 4).

Day	cell number/ml
1	3 x 10 ⁵
2	1 x 10 ⁵
3	5 x 10 ⁴
4	1 x 10 ⁴

20

Culture medium was removed and plates blocked with DMEM/F12 (Sigma D6421) containing FCS (10%), BSA (1%), NaN₃ (1%; blocking buffer) for 1 hour at RT. Blocking solution was then removed and sample added (in blocking buffer

- 5 50µl/well). Incubated samples at 4°C for 1 h. Plates were then washed 3x with PBS using a Skatron plate washer. After wash, cells were fixed with 0.5% paraformaldehyde (diluted in PBS) for 20 minutes at 4°C and again washed as above. 50µl/well Europium-conjugated secondary antibody diluted in Europium buffer (50mM Tris base, 150mM NaCl, 0.5% BSA, 0.1g/l, Tween 20, 7.86mg/l DTPA at pH 7.3) was added and incubated for 1 h at 4°C.
- 10 Washed plates as above and added 200µl Delphia enhancement solution/well. Incubated solution at RT for 5 – 10 minutes. Wells were read within 24 hours on a Victor .

15 ***4) Competition ELISA for binding to rat MAG-Fc fusion protein of two purified humanised antibodies and the non-humanised mouse monoclonal antibody***

Method:

- 20 96-well Nunc Maxisorp plates were coated overnight at 4°C with rat MAG-Fc fusion protein (2.5 µg/ml; R&D Systems; Cat.No. 538-MG) in PBS. Plates were washed twice with PBS containing Tween20 (0.1% v/v; PBST) and blocked with PBS containing BSA (1%w/v) for 1h at room temperature (RT). Purified humanised antibody was adjusted to a concentration of 200ng/ml and mixed at
- 25 equal volume with competitor molecules made up in blocking buffer ranging from 6000 to 0 ng/ml. Competitors were either parental mouse monoclonal antibody (anti-MAG) or an unrelated mouse monoclonal antibody (INN1) at the same concentrations (BVh1/CV11 only). Antibody/competitor solutions were incubated 1h at RT and plates then washed 3x with PBST. Secondary antibody (Goat anti-
- 30 human light chain specific-peroxidase conjugate; Sigma A-7164) was added diluted 1/5000 in blocking buffer and incubated for 1h at RT. Wells were washed three times as above and binding detected by adding substrate (OPD tablets

- 5 dissolved according to instructions; Sigma P-9187). Colour development was measured at 490 nm.

Results:

- Both purified antibody preparations are equally competed by the original mouse
10 monoclonal antibody but not by a mouse monoclonal antibody that has an unrelated specificity - see Figure 9. This shows that the original mouse monoclonal antibody and the humanised antibodies tested here are probably recognising the same epitope and possibly have very similar affinities to rat MAG.

5 **CLAIMS**

1. An altered antibody or functional fragment thereof which binds to and neutralises MAG and which comprises one or more of the following CDR's.

10 ***Light chain CDRs***

<i>CDR</i>	<i>According to Kabat</i>
L1	KSSHVLYSSNQKNYLA
L2	WASTRES
L3	HQYLSSLT

Heavy chain CDRs

<i>CDR</i>	<i>According to Kabat</i>
H1	NYGMN
H2	WINTYTGEPTYADDFTG
H3	NPINYGINYEGYVMDY

15

2. An altered antibody or functional fragment thereof which comprises a heavy chain variable domain which comprises one or more CDR's selected from CDRH1, CDRH2 and CDRH3 and/or a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3 .

20

3. An altered anti-Mag antibody or functional fragment thereof which comprises:

a heavy chain variable domain (V_H) which comprises in sequence hypervariable regions CDRH1, CDRH2 and CDRH3 and /or

25

- 5 a light chain variable domain (V_L) which comprises in sequence hypervariable regions CDRL1, CDRL2 and CDRL3.
4. An antibody of claim 3 which is monoclonal.
- 10 5. An antibody of claim 4 which is humanised.
6. An antibody or functional fragment thereof that according to claim 5 which comprises a heavy chain variable region comprising one of the following amino acid sequences
- 15 QVQLVQSGSELKKPGASVKVSCASGYTFT**NYGMNWVRQAPGQGLEWMGWI**
NTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARN**PIN**
YGINYEGYVMDYWGQGLTVTVSS (SEQ ID No 13).
- 20 QVQLVQSGSELKKPGASVKVSCASGYTFT**NYGMNWVRQAPGQGLEWMGWI**
NTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARN**PIN**
YGINYEGYVMDYWGQGLTVTVSS (Sequence ID No 14)
- 25 QVQLVQSGSELKKPGASVKVSCASGYTFT**NYGMNWVRQAPGQGLEWMGWI**
NTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTATYFCARN**PIN**
YGINYEGYVMDYWGQGLTVTVSS (sequence ID No 15)
7. An antibody or functional fragment thereof according to claim 6 further comprising a light chain variable region comprising amino acid Sequence
- 30 ID No 16, 17, 18 or 19:

35

DIVMTQSPDSLAVSLGERATINCK**SSH**SVLYSS**NQKNYL**AWYQQKPGQPPK
LLIY**WASTRES**GVDPDRFSGSGSGTDFTLTIISSSLQAEDVAVYYC**HQYLSSLT**
FGQGTKLEIKRTV (SEQ ID No 16)

DIVMTQSPDSLAVSLGERATINCK**SSH**SVLYSS**NQKNYL**AWYQQKPGQPPK
LLIY**WASTRES**GVDPDRFSGSGSGTDFTLTIIINLQAEDVAVYYC**HQYLSSLT**
FGQGTKLEIKRTV (SEQ ID No 12)

5 DIVMTQSPDSLAVSLGERATINCKSSHVLYSSNQKNYLAWYQQKPGQPPK
 LLIYWASTRESGVDPDRFSGSGSGTDFTLTITSSLTEDVAVYYCHQYLSSTL
 FGQGTKLEIKRTV (SEQ ID No 18)

10 DIVMTQSPDSLAVSLGERATINCKSSHVLYSSNQKNYLAWYQQKPGQPPK
 LLIYWASTRESGVDPDRFSGSGSGTDFTLTITINLHTEDVAVYYCHQYLSSTL
 FGQGTKLEIKRTV (SEQ ID No 19)

8. An antibody according to claims 6 – 7 comprising:
 a heavy chain variable fragment comprising SEQ ID No 13,14 or 15
 15 and a constant part or fragment thereof of a human heavy chain
 and
 a light chain variable fragment comprising SEQ ID No 16, 17, 18 or 19 and
 a constant part or fragment thereof of a human light chain.
- 20 9. An humanised antibody according to any preceding claim selected from
 antibodies comprising:
 Heavy chain variable region comprising Seq ID No 13 and light chain
 variable region comprising Seq ID No 16;
 Heavy chain variable region comprising Seq ID No 13 and light chain
 25 variable region comprising Seq ID No 17;
 Heavy chain variable region comprising Seq ID No 13 and light chain
 variable region comprising Seq ID No 18;
 Heavy chain variable region comprising Seq ID No 13 and light chain
 variable region comprising Seq ID No 19.
 30 Heavy chain variable region comprising Seq ID No 14 and light chain
 variable region comprising Seq ID No 16;
 Heavy chain variable region comprising Seq ID No 14 and light chain
 variable region comprising Seq ID No 17;
 Heavy chain variable region comprising Seq ID No 14 and light chain
 35 variable region comprising Seq ID No 18;
 Heavy chain variable region comprising Seq ID No 14 and light chain
 variable region comprising Seq ID No 19.

- 5 Heavy chain variable region comprising Seq ID No 15 and light chain
variable region comprising Seq ID No 16;
Heavy chain variable region comprising Seq ID No 15 and light chain
variable region comprising Seq ID No 17;
Heavy chain variable region comprising Seq ID No 15 and light chain
10 variable region comprising Seq ID No 18;
Heavy chain variable region comprising Seq ID No 15 and light chain
variable region comprising Seq ID No 19.

10. A polynucleotide encoding the heavy chain variable region comprising
15 Sequence ID No 15.

CAGGTGCAGCTGGTGCAATCTGGGTCTGAGTTGAAGAAGCCTGGGGCCTCA
GTGAAGGTTTCCTGCAAGGCTTCTGGATACACCTTCACTAAACTACGGCATG
AACTGGGTGCGACAGGCCCTGGACAAGGGCTTGAGTGGATGGGATGGATC
20 AACACCTACACCGGCGAGCCACCTACGCCGACGACTTCACCGGCCGGTTT
GTCTTCTCCTTGGACACCTCTGTCAGCACGGCATATCTGCAGATCAGCAGC
CTAAAGGCTGAGGACACTGCCGTGTATTACTGTGCGAGAAACCCCATCAAC
TACTACGGCATCAACTACGAGGGCTACGTGATGGACTACTGGGGCCAGGGC
ACACTAGTCACAGTCTCCTCA

- 25 11. A polynucleotide sequence encoding the amino acid Sequence ID No 14 is:

CAGGTGCAGCTGGTGCAATCTGGGTCTGAGTTGAAGAAGCCTGGGGCCTCA
GTGAAGGTTTCCTGCAAGGCTTCTGGATACACCTTCACTAAACTACGGCATG
AACTGGGTGCGACAGGCCCTGGACAAGGGCTTGAGTGGATGGGATGGATC
30 AACACCTACACCGGCGAGCCACCTACGCCGACGACTTCACCGGCCGGTTT
GTCTTCTCCTTGGACACCTCTGTCAGCACGGCATATCTGCAGATCAGCAGC
CTAAAGGCTGAGGACACTGCCGTGTATTTCTGTGCGAGAAACCCCATCAAC
TACTACGGCATCAACTACGAGGGCTACGTGATGGACTACTGGGGCCAGGGC
ACACTAGTCACAGTCTCCTCA

- 35 12. A polynucleotide sequence encoding the amino acid Sequence ID No 15 is:

CAGGTGCAGCTGGTGCAATCTGGGTCTGAGTTGAAGAAGCCTGGGGCCTCA
GTGAAGGTTTCCTGCAAGGCTTCTGGATACACCTTCACTAAACTACGGCATG
AACTGGGTGCGACAGGCCCTGGACAAGGGCTTGAGTGGATGGGATGGATC
40 AACACCTACACCGGCGAGCCACCTACGCCGACGACTTCACCGGCCGGTTT
GTCTTCTCCTTGGACACCTCTGTCAGCACGGCATATCTGCAGATCAGCAGC

5 CTAAAGGCTGAGGACACTGCCACCTATTTCTGTGCGAGAAACCCCATCAAC
TACTACGGCATCAACTACGAGGGCTACGTGATGGACTACTGGGGCCAGGGC
ACACTAGTCACAGTCTCCTCA

10 13 A polynucleotide encoding amino acid Sequence ID No 16 is:

GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAG
AGGGCCACCATCAACTGCAAGAGCAGCCACAGCGTGCTGTACAGCAGCAAC
CAGAAGAACTACCTGGCCTGGTACCAGCAGAAACCAGGACAGCCTCCTAAG
CTGCTCATTTACTTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCT
15 AGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAG
GCTGAAGATGTGGCAGTTTATTACTGTCAACAGTACCTGAGCAGCCTGACC
TTTGGCCAGGGGACCAAGCTGGAGATCAAACGTACGGTG

20 14. A polynucleotide sequence encoding amino acid SEQ ID No 17 is:

GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAG
AGGGCCACCATCAACTGCAAGAGCAGCCACAGCGTGCTGTACAGCAGCAAC
CAGAAGAACTACCTGGCCTGGTACCAGCAGAAACCAGGACAGCCTCCTAAG
CTGCTCATTTACTTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCT
25 AGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCATCAACCTGCAG
GCTGAAGATGTGGCAGTTTATTACTGTCAACAGTACCTGAGCAGCCTGACC
TTTGGCCAGGGGACCAAGCTGGAGATCAAACGTACGGTG

30 15. A polynucleotide encoding amino acid SEQ ID No 18 is:

GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAG
AGGGCCACCATCAACTGCAAGAGCAGCCACAGCGTGCTGTACAGCAGCAAC
CAGAAGAACTACCTGGCCTGGTACCAGCAGAAACCAGGACAGCCTCCTAAG
CTGCTCATTTACTTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCT
35 AGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAC
ACCGAAGATGTGGCAGTTTATTACTGTCAACAGTACCTGAGCAGCCTGACC
TTTGGCCAGGGGACCAAGCTGGAGATCAAACGTACGGTG

40 16. A polynucleotide encoding amino acid SEQ ID No 15 is:

GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAG
AGGGCCACCATCAACTGCAAGAGCAGCCACAGCGTGCTGTACAGCAGCAAC
CAGAAGAACTACCTGGCCTGGTACCAGCAGAAACCAGGACAGCCTCCTAAG
CTGCTCATTTACTTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCT
45 AGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCATCAACCTGCAC
ACCGAAGATGTGGCAGTTTATTACTGTCAACAGTACCTGAGCAGCCTGACC
TTTGGCCAGGGGACCAAGCTGGAGATCAAACGTACGGTG

5

17. A pharmaceutical composition comprising an altered anti-MAG antibody or functional fragment thereof according to claims 1-8 together with a pharmaceutically acceptable diluent or carrier.

10 18. A method of treatment or prophylaxis of stroke and other neurological diseases/disorders in a human which comprises administering to said human in need thereof an effective amount of an anti-MAG antibody, according to claims 1-8 including altered antibodies or a functional fragment thereof.

15

19. The use of an anti-MAG antibody according to claims 1-8, including altered antibodies or a functional fragment thereof in the preparation of a medicament for treatment or prophylaxis of stroke and other neurological diseases/disorders.

20

20. A method of inhibiting neurodegeneration and/or promoting functional recovery in a human patient suffering, or at risk of developing, a stroke or other neurological disease/disorder which comprises administering to said human in need thereof an effective amount of an anti-MAG antibody according to claims 1-6, including altered antibodies or a functional fragment thereof.

25

21. The use of an anti-MAG antibody according to claims 1-8, including altered antibodies or a functional fragment thereof in the preparation of a medicament for inhibiting neurodegeneration and/or promoting functional recovery in a human patient afflicted with, or at risk of developing, a stroke and other neurological disease/disorder.

30

- 5 22. A method of treating or prophylaxis of stroke or other neurological disease/disorder in a human comprising the step of parenteral administration of a therapeutically effective amount of an anti-MAG antibody to said human.
- 10 23. The method of claim 22 wherein the anti-MAG antibody is administered intravenously.
- 15 24. The method of claim 18, 20 or 24 wherein the other neurological disease/disorder is selected from the group consisting of; traumatic brain injury, spinal cord, Alzheimer's disease, fronto-temporal dementias (tauopathies), peripheral neuropathy, Parkinson's disease, Huntington's disease and multiple sclerosis.
- 20 25. A method of promoting axonal sprouting comprising the step of contacting a human axon with an anti-MAG antibody of claims 1 to 8.
26. The method of claim 25 wherein the method is *in vitro*.

Figure 1

MGWSCIIILFLVATATGVHSEIQLVQSGPELKKPGETNKISCKASGYTFTNYGMNWVKQAPGKGLKW
MGWINTYTGEPTYADDFTGRFAFSLETSASTAYLQISNLKNEDTATYFCARNPINYYGINYEGYVM
DYWGQGTLLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
PAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG
APSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEALHN
HYTQKSLSLSPGK

Figure 2

MGWSCIIILFLVATATGVHSNIMMTQSPSSLAVSAGEKVTMSCKSSHVLYSSNQKNYLAWYQQKPG
QSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTIIINVHTEDLAVYYCHQYLSSLTFTGTGKLEIKR
TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYS
LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Figure 3

MGWSCIIILFLVATATGVHSEIQLVQSGPELKKPGETNKISCKASGYTFTNYGMNWVKQAPGKGLKW
MGWINTYTGEPTYADDFTGRFAFSLETSASTAYLQISNLKNEDTATYFCARNPINYYGINYEGYVM
DYWGQGTLLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
PAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEALHN
HYTQKSLSLSPGK

Figure 4




Figure 5**Seq ID No: 30**

MGWSCIIILFLVATATGVHSQVQLVQSGSELKKPGASVKVSCKASGYTFTNYGM
NWVRQAPGQGLEWMGWINTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSL
KAEDTAVYYCARNPINYYGINYEGYVMDYWGQGLTVTVSSASTKGPSVFPLAP
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGA
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP
REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPP
VLDSGDSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK


Seq ID No: 31

MGWSCIIILFLVATATGVHSDIVMTQSPDSLAVSLGERATINCKSSHSVLYSSN
QKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISLQAE
DVAVYYCHQYLSSLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEK
HKVYACEVTHQGLSSPVTKSFNRGEC

Seq ID No: 32

MGWSCIIILFLVATATGVHSQVQLVQSGSELKKPGASVKVSCKASGYTFTNYGM
NWVRQAPGQGLEWMGWINTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSL
KAEDTAVYYCARNPINYYGINYEGYVMDYWGQGLTVTVSSASTKGPSVFPLAP
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP
REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPP
VLDSGDSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

Figure 6



Purified antibody material at concentrations determined by OD280

Figure 7




Figure 8





Figure 9

Competition ELISA for binding to rat MAG-Fc fusion protein of two purified humanised antibodies and the non-humanised mouse monoclonal antibody



03 FEB 2005

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 February 2004 (19.02.2004)

PCT

(10) International Publication Number
WO 2004/014953 A3

(51) International Patent Classification⁷: **A61K 39/395**,
A61P 25/00, C07K 16/28

(74) Agents: **LEAROYD, Stephanie, Anne et al.**; Glaxo-
SmithKline, 980 Great West Road, Brentford, Middlesex
TW8 9GS (GB).

(21) International Application Number:
PCT/EP2003/008749

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 5 August 2003 (05.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0218230.1 6 August 2002 (06.08.2002) GB
0218232.7 6 August 2002 (06.08.2002) GB
0218234.3 6 August 2002 (06.08.2002) GB
0218229.3 6 August 2002 (06.08.2002) GB

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **GLAXO
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ELLIS, Jonathan,
Henry** [GB/GB]; GlaxoSmithKline, Gunnels Wood
Road, Stevenage, Hertfordshire SG1 2NY (GB). **GER-
MASCHEWSKI, Volker** [DE/GB]; GlaxoSmithKline,
Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY
(GB).

(88) Date of publication of the International search report:
6 May 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

WO 2004/014953 A3

(54) Title: ANTI-MYELIN ASSOCIATED GLYCOPROTEIN (MAG) ANTIBODIES

(57) Abstract: The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/08749

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K39/395 A61P25/00 C07K16/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 22344 A (BRAUN PETER ERICH ; MCKERRACHER LISA JOAN (CA); UNIV MCGILL (CA); D) 24 August 1995 (1995-08-24) page 16, line 21 - page 18, line 34 page 21, line 3 - line 14; claims 4-7 ---	1-6, 12-16
X	WO 01 62907 A (MEDICAL & BIOLOG LAB CO LTD ; IBA YOSHITAKA (JP); AKAHORI YASUSHI () 30 August 2001 (2001-08-30) figure 54 ---	1-5
A	WO 98 12329 A (REED GUY L) 26 March 1998 (1998-03-26) figures 15,16 ---	1-6
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

5 March 2004

Date of mailing of the international search report

19/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Le Flao, K

INTERNATIONAL SEARCH REPORT

International Publication No.

PCT/EP 03/08749

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 02 062383 A (VINSON MARY ; IRVING ELAINE ALISON (GB); SMITHKLINE BEECHAM PLC (GB) 15 August 2002 (2002-08-15) claim 7 ---	1-5, 17-26
A	WO 99 25378 A (EURO CELTIQUE SA) 27 May 1999 (1999-05-27) claim 6 ---	1-26
A	WO 99 53945 A (BRAUN PETER ERICH ; MCKERRACHER LISA JOAN (CA); DAVID SAMUEL (CA)) 28 October 1999 (1999-10-28) claims 1-23 -----	1-26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/08749

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 18, 20, 22-25 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Publication No

PCT/EP 03/08749

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9522344	A	24-08-1995	AU 1703595 A CA 2183630 A1 WO 9522344 A1	04-09-1995 24-08-1995 24-08-1995
WO 0162907	A	30-08-2001	AU 3412501 A EP 1264885 A1 WO 0162907 A1	03-09-2001 11-12-2002 30-08-2001
WO 9812329	A	26-03-1998	AU 734997 B2 AU 4413497 A AU 741338 B2 AU 4413597 A CA 2266339 A1 CA 2266341 A1 EP 0937146 A2 EP 0941345 A2 JP 2001515345 T JP 2001502895 T WO 9812329 A2 WO 9812334 A2 US 6114506 A US 2003017147 A1 US 2003031664 A1	28-06-2001 14-04-1998 29-11-2001 14-04-1998 26-03-1998 26-03-1998 25-08-1999 15-09-1999 18-09-2001 06-03-2001 26-03-1998 26-03-1998 05-09-2000 23-01-2003 13-02-2003
WO 02062383	A	15-08-2002	EP 1357941 A2 WO 02062383 A2	05-11-2003 15-08-2002
WO 9925378	A	27-05-1999	AU 763029 B2 AU 1459799 A AU 737457 B2 AU 1459899 A BR 9815289 A BR 9815580 A CA 2309990 A1 CA 2310269 A1 CN 1294517 T CN 1327388 T EP 1032420 A1 EP 1030684 A1 JP 2001526021 T JP 2002507544 T WO 9925378 A1 WO 9925379 A1 US 2002028469 A1 ZA 9900048 A ZA 9900049 A	10-07-2003 07-06-1999 23-08-2001 07-06-1999 26-12-2001 29-01-2002 27-05-1999 27-05-1999 09-05-2001 19-12-2001 06-09-2000 30-08-2000 18-12-2001 12-03-2002 27-05-1999 27-05-1999 07-03-2002 08-07-1999 09-03-2000
WO 9953945	A	28-10-1999	AU 3134799 A WO 9953945 A1	08-11-1999 28-10-1999